<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis - Chen, X - 2013 | Cochrane Library</title> <meta content="Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis - Chen, X - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009481.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis - Chen, X - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009481.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009481.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis" name="citation_title"/> <meta content="Xiaomei Chen&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Ming Yang&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Yan Cheng" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Guan J Liu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Min Zhang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="hxlily@163.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD009481.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/10/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009481.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009481.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009481.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Photochemotherapy [*methods]; Photosensitizing Agents [*therapeutic use]; Psoriasis [*drug therapy, pathology]; Randomized Controlled Trials as Topic; Treatment Outcome; Ultraviolet Therapy [*methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009481.pub2&amp;doi=10.1002/14651858.CD009481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009481\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009481\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009481.pub2",title:"Narrow\\u2010band ultraviolet B phototherapy versus broad\\u2010band ultraviolet B or psoralen\\u2010ultraviolet A photochemotherapy for psoriasis",firstPublishedDate:"Oct 23, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009481.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009481.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009481.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009481.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009481.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009481.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009481.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009481.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2511 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009481.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-sec-0165"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-sec-0075"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-sec-0159"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/appendices#CD009481-sec-0170"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/table_n/CD009481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/table_n/CD009481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="❖ Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#CD009481-cr-0002">Xiaomei Chen</a><sup>a</sup></li> <li class="author custom-tooltip" title="✢ Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#CD009481-cr-0003">Ming Yang</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#CD009481-cr-0004">Yan Cheng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#CD009481-cr-0005">Guan J Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information#CD009481-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Min Zhang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information/en#CD009481-sec-0181">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 October 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009481.pub2">https://doi.org/10.1002/14651858.CD009481.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009481-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009481-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009481-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009481-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009481-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009481-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009481-abs-0001" lang="en"> <section id="CD009481-sec-0001"> <h3 class="title" id="CD009481-sec-0001">Background</h3> <p>The most commonly used types of phototherapy for treating psoriasis are narrow‐band ultraviolet B (NB‐UVB); broad‐band ultraviolet B (BB‐UVB), which includes selective (delivering radiation with a wavelength range of 305 to 325 nm) and conventional BB‐UVB (280 to 320 nm); and psoralen ultraviolet A photochemotherapy (oral or bath PUVA). There is substantial controversy regarding their efficacy when compared with each other. </p> </section> <section id="CD009481-sec-0002"> <h3 class="title" id="CD009481-sec-0002">Objectives</h3> <p>To assess the effects of narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen ultraviolet A photochemotherapy for psoriasis. </p> </section> <section id="CD009481-sec-0003"> <h3 class="title" id="CD009481-sec-0003">Search methods</h3> <p>We searched the following databases up to August 2013: the Cochrane Skin Group Specialised Register, CENTRAL in <i>The Cochrane Library</i> (2013, Issue 7), MEDLINE (from 1946), and EMBASE (from 1974). We searched the following databases up to November 2012: CNKI (from 1974) and CBM (from 1978). We also searched trials registers and the OpenGrey database. </p> </section> <section id="CD009481-sec-0004"> <h3 class="title" id="CD009481-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) that compared NB‐UVB phototherapy with BB‐UVB or PUVA for treating psoriasis, which included chronic plaque psoriasis (CPP), guttate psoriasis (GP), and palmoplantar psoriasis (PPP). </p> </section> <section id="CD009481-sec-0005"> <h3 class="title" id="CD009481-sec-0005">Data collection and analysis</h3> <p>Two review authors independently conducted the study selection, 'Risk of bias' assessment, and data extraction. </p> </section> <section id="CD009481-sec-0006"> <h3 class="title" id="CD009481-sec-0006">Main results</h3> <p>We included 13 RCTs, with a total of 662 participants. We report the results of intention‐to‐treat analyses (ITT) here. Our primary outcomes of interest were as follows: Participant‐rated global improvement, Percentage of participants reaching Psoriasis Area and Severity Index (PASI) 75 (which meant equal to or more than 75% reduction in PASI score), Withdrawal due to side‐effects, and Clearance rate. </p> <p>In one RCT of NB‐UVB compared with oral PUVA in participants with CPP, the difference in PASI 75 was not statistically significant (risk ratio (RR) 0.91, 95% confidence interval (CI) 0.63 to 1.32; N = 51; low quality). In three other RCTs of CPP, the clearance rates were inconsistent because in one, there was no difference between the groups (RR 1.01, 95% CI 0.91 to 1.12; N = 54), and in the other two, the clearance rates were statistically significantly in favour of oral PUVA: RR 0.66, 95% CI 0.47 to 0.93; N = 93 and RR 0.75, 95% CI 0.59 to 0.96; N = 100, respectively. Pooled data from these three studies indicated that withdrawals due to adverse events were not significantly different between either group (RR 0.71, 95% CI 0.20 to 2.54; N = 247; low quality). </p> <p>The evidence from the comparison of NB‐UVB with bath PUVA in terms of clearance rate for CPP was also inconsistent: Pooled data from two left‐right body comparison RCTs found no significant difference between the NB‐UVB and bath PUVA groups (RR 1.79, 95% CI 0.46 to 6.91; N = 92; low quality), while a parallel RCT favoured bath PUVA (RR 0.18, 95% CI 0.05 to 0.71; N = 36; low quality). </p> <p>In participants with PPP, one RCT found there were no significant differences between NB‐UVB treated sides and topical PUVA treated sides in terms of clearance rate (RR 0.09, 95% CI 0.01 to 1.56; N = 50; low quality). </p> <p>Two RCTs found NB‐UVB plus retinoid (re‐NB‐UVB) and PUVA plus retinoid (re‐PUVA) had similar effects for treating people with CPP or GP in terms of clearance rate (RR 0.93, 95% CI 0.79 to 1.10; N = 90; low quality). </p> <p>One RCT in people with CPP found no significant differences between NB‐UVB and selective BB‐UVB in terms of clearance rate (RR 1.40, 95% CI 0.92 to 2.13; N = 100; low quality) and withdrawals due to adverse events (RR 3.00, 95% CI 0.32 to 27.87; N = 100; low quality). </p> <p>No studies reported our primary outcomes for NB‐UVB compared with conventional BB‐UVB.</p> </section> <section id="CD009481-sec-0007"> <h3 class="title" id="CD009481-sec-0007">Authors' conclusions</h3> <p>Current evidence is very heterogeneous and needs to be interpreted with caution. The clearance rate between oral PUVA and NB‐UVB is inconsistent among the included studies. Evidence regarding NB‐UVB versus bath PUVA is also inconsistent. Re‐NB‐UVB and re‐PUVA are similarly effective for treating people with CPP or GP. In practice, NB‐UVB may be more convenient to use since exogenous photosensitiser is not required before phototherapy. </p> <p>NB‐UVB is considered ineffective for PPP in clinical practice, and a small RCT did not detect a statistically significant difference between NB‐UVB and topical PUVA for clearing PPP. NB‐UVB seemed to be similar to selective BB‐UVB for clearing CPP. </p> <p>Larger prospective studies are needed to confirm the long‐term safety of NB‐UVB.</p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009481-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009481-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009481-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009481-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009481-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009481-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009481-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009481-abs-0003" lang="en"> <h3>Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen ultraviolet A photochemotherapy for treating psoriasis </h3> <p>Psoriasis is a common, chronic inflammatory skin disease, with an estimated global prevalence ranging from 0.5% to 4.6%. Based on clinical features, psoriasis is generally divided into the following: chronic plaque psoriasis (CPP); psoriasis associated with psoriatic arthritis; and pustular, erythrodermic, or guttate psoriasis. We also considered psoriasis affecting the palms and soles (palmoplantar psoriasis, or PPP). Although psoriasis is rarely life‐threatening, it can affect a person's quality of life significantly. </p> <p>Phototherapy is an essential treatment option for people with psoriasis. The most commonly used types of phototherapy are narrow‐band ultraviolet B (NB‐UVB), broad‐band ultraviolet B (BB‐UVB), and psoralen ultraviolet A photochemotherapy (PUVA). PUVA can be further divided into oral, bath, and topical PUVA according to the administrative route of psoralen. NB‐UVB delivers almost exclusively 311 nm radiation, whereas BB‐UVB can be divided into two types: selective BB‐UVB (305 to 325 nm radiation) and conventional BB‐UVB (280 to 320 nm radiation). </p> <p>This review included 13 small randomised controlled trials (RCT), with a total of 662 participants. Most of these were of poor methodological quality. </p> <p>For treating CPP, the clearance rate between the NB‐UVB and oral PUVA groups were inconsistent in three RCTs. In one, there was no difference between the groups, and in the other two, the clearance rate was in favour of oral PUVA. The evidence from the comparison of NB‐UVB with bath PUVA in terms of clearance rate was also inconsistent: Pooled data from two left‐right body comparison RCTs found no significant difference between the two groups, while another RCT favoured bath PUVA. </p> <p>Two RCTs found NB‐UVB plus retinoid (re‐NB‐UVB) and PUVA plus retinoid (re‐PUVA) had similar effects for treating people with CPP or guttate psoriasis. One RCT found no significant differences between NB‐UVB and selective BB‐UVB for clearing CPP or in the number of withdrawals due to side‐effects. </p> <p>In participants with PPP, one RCT found there were no statistically significant differences between NB‐UVB treated sides and topical PUVA treated sides in terms of clearance rate. </p> <p>In summary, NB‐UVB may be preferred to oral or bath PUVA because it is more convenient to use. NB‐UVB seemed to be equal to selective BB‐UVB for clearing CPP. Evidence regarding NB‐UVB and conventional BB‐UVB is limited. The long‐term safety of NB‐UVB needs to be confirmed. The efficacy of NB‐UVB for clearing PPP needs to be confirmed in future studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009481-sec-0165" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009481-sec-0165"></div> <h3 class="title" id="CD009481-sec-0166">Implications for practice</h3> <section id="CD009481-sec-0166"> <p> <ul id="CD009481-list-0012"> <li> <p>Current available evidence is very heterogeneous and has to be interpreted or applied with caution. </p> </li> <li> <p>According to current limited evidence, in people with chronic plaque psoriasis, oral PUVA, compared with NB‐UVB, leads to longer lasting clearance, a fewer number of treatments, and higher levels of QOL, but more nausea and a similar relapse rate at six months. The clearance rate between oral PUVA and NB‐UVB is contradictory among the included studies. Evidence regarding NB‐UVB versus bath PUVA is contradictory. Retinoids with NB‐UVB and retinoids with PUVA have a similar effect for treating people with chronic plaque or guttate psoriasis. However, the long‐term side‐effects of PUVA, especially the potential risk of carcinogenesis, need to be taken into account. In practice, NB‐UVB may be more convenient to use since exogenous photosensitiser is not required before phototherapy. </p> </li> <li> <p>Although NB‐UVB is considered ineffective for palmoplantar psoriasis in clinical practice, a small included RCT did not detect a statistically significant difference in the efficacy of NB‐UVB and topical PUVA in clearing palmoplantar psoriasis. This needs to be investigated in the future. </p> </li> <li> <p>NB‐UVB is more effective than or at least equal to selective BB‐UVB, irrespective of whether it is combined with dithranol. </p> </li> <li> <p>Evidence regarding NB‐UVB and conventional BB‐UVB is limited and of poor quality; none of the included studies addressed the primary outcomes in this comparison. </p> </li> </ul> </p> </section> <h3 class="title" id="CD009481-sec-0167">Implications for research</h3> <section id="CD009481-sec-0167"> <p>This review highlights the need for further high‐quality research regarding the use of NB‐UVB and PUVA for treating psoriasis. The following key points should be taken into account in future research: a big enough sample size to identify the presumptive difference, strict standardisation of the method of UV irradiation, and appropriate outcomes that matter to people (e.g. quality of life and the cost‐effectiveness of the therapy). Good practice guidelines (e.g. CONSORT) must be followed during the process of study design, implementation, and reporting. In addition, prospective studies regarding the carcinogenic risk of NB‐UVB therapy are urgently needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009481-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009481-sec-0029"></div> <div class="table" id="CD009481-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NB‐UVB compared with oral PUVA for chronic plaque psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>NB‐UVB compared with oral PUVA for chronic plaque psoriasis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Oral PUVA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral PUVA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>655 per 1000</b> <br/> (454 to 950) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> <br/> (0.63 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> <p>(7 to 82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> <br/> (0.20 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (3 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The results of 3 small RCTs are contradictory. Because of the significant statistical heterogeneity, the data were not pooled </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ The study was of small sample size.<br/> ² The study was at high risk of bias.<br/> ³ All of the 3 studies were of small sample size and at high risk of bias, and the result was based on less than 300 participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009481-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NB‐UVB compared with bath PUVA for chronic plaque psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB compared with bath PUVA for chronic plaque psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Bath PUVA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bath PUVA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (160 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> <br/> (0.46 to 6.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. On the basis of studies performing left‐right body comparison. 2. This is the result of ITT analysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>611 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (31 to 434) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.18</b> <br/> (0.05 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>², ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. On the basis of the study performing comparison between participants. 2. This is the result of ITT analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ Both of the studies were of small sample size and at high risk of bias, and the result was based on less than 300 participants.<br/> ² The study was at high risk of bias.<br/> ³ The study was of small sample size, and the result was based on less than 300 participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009481-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NB‐UVB compared with topical PUVA for palmoplantar psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB compared with topical PUVA for palmoplantar psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with palmoplantar psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Topical PUVA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical PUVA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> <br/> (2 to 312) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b> <br/> (0.01 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ This study was at unclear risk of bias.<br/> ² The study was of small sample size, and the result was based on less than 300 participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009481-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">NB‐UVB plus retinoid compared with PUVA plus retinoid for chronic plaque or guttate psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB plus retinoid compared with PUVA plus retinoid for chronic plaque or guttate psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque or guttate psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB plus retinoid<br/> <b>Comparison:</b> PUVA plus retinoid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PUVA plus retinoid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB plus retinoid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.59 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>633 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> <br/> (374 to 855) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>756 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>688 per 1000</b> <br/> (544 to 831) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.79 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>², ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ This study was at high risk of bias.<br/> ² The studies were of small sample size, and the result was based on less than 300 people.<br/> ³ Both of the studies were at high risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009481-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Selective BB‐UVB </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Selective BB‐UVB</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.00</b> <br/> (0.32 to 27.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> <br/> (6 to 557) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b> <br/> (368 to 852) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> <br/> (0.92 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ The study was at unclear risk of bias.<br/> ² The study was of small sample size, and the result was based on less than 300 people. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009481-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009481-sec-0030"></div> <p>Please note that unfamiliar terms and abbreviations are listed in <a href="#CD009481-tbl-0006">Table 1</a> ('Glossary of some important terms and abbreviations used'). </p> <div class="table" id="CD009481-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of some important terms and abbreviations used</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medical term and abbreviations</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Apoptosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of programmed cell death that occurs during growth and development of multicellular organisms. It is generally considered a part of normal cell aging, but it can also be a response to cellular injury </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BB‐UVB</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Broad‐band ultraviolet B</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Collagenase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme that breaks the peptide bonds in collagen</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CPP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic plaque psoriasis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cytokines</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small protein molecules that are secreted by cells of the nervous system or the immune system. They are used in intercellular communication </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Defective maturation of epidermal keratinocytes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete formation of keratin (the horny material in nails) due to rapid growth of cells in the epidermal layer of the skin </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dilatation of dermal capillaries</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dilation of small blood vessels in the skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythrodermic psoriasis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A subtype of psoriasis that affects nearly all body sites</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythrogenic response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness of the skin caused by light exposure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extensor aspects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An anatomical term ‐ when a joint bends, the parts of the skin on the opposite side of the joint are called the extensor aspects </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperkeratosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thickening of the stratum corneum (outermost layer of the skin) usually associated with an abnormality of the keratin and an increase of the granular layer of the skin </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperplasia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An increase in the number of cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperproliferation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An abnormally high rate of proliferation of cells by rapid division</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypertriglyceridaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High levels of triglyceride fatty acids</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intention‐to‐treat: An ITT analysis is often recommended as the least biased way to estimate intervention effects in RCTs. The principals of ITT analysis are as follows: 1. keep participants in the intervention group to which they were randomised, regardless of the intervention they actually received; 2. measure outcome data on all participants; and 3. include all randomised participants in the analysis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal residual activity</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MOP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methoxypsoralen</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NB‐UVB</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narrow‐band ultraviolet B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Paronychia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling of the skin over the nail</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PASI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psoriasis Area and Severity Index. The higher the score, the more severe the lesions are </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PASI 75</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equal to or more than 75% reduction in PASI score</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmoplantar psoriasis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psoralen</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A compound that can be used as a kind of photosensitiser to improve the influence of natural or artificial light </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PUVA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psoralen plus ultraviolet A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Photosensitiser</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical treatments that are used to sensitise the skin and enhance the effect of light treatments </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pustular</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesions containing purulent materials</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QOL</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Re‐NB‐UVB</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NB‐UVB combined with retinoid</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Re‐PUVA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PUVA combined with retinoid</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity index of PPP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A tool developed by <a href="./references#CD009481-bbs2-0047" title="HoferA , Fink‐PuchesR , KerlH , QuehenbergerF , WolfP . Paired comparison of bath water versus oral delivery of 8‐methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis.. Photodermatol Photoimmunol Photomed2006;22:1‐5. ">Hofer 2006</a> to evaluate the severity of palmoplantar psoriasis. The separate scores of erythema, scaling, pustulation, and infiltration for palms and soles were added to calculate the severity index (0 = absent; 1 = slight; 2 = moderate; 3 = marked; and 4 = very marked) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Xerophthalmia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dryness of the eye, especially the cornea and conjunctiva</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Xerosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extreme dryness of the skin</p> </td> </tr> </tbody> </table> </div> <section id="CD009481-sec-0031"> <h3 class="title" id="CD009481-sec-0031">Description of the condition</h3> <section id="CD009481-sec-0032"> <h4 class="title">Description and epidemiology</h4> <p>Psoriasis is a common, chronic inflammatory skin disease, with an estimated global prevalence ranging from 0.5% to 4.6% (<a href="./references#CD009481-bbs2-0054" title="LebwohlM . Psoriasis. Lancet2003;361(9364):1197‐204. [MEDLINE: 12686053] ">Lebwohl 2003</a>). The typical lesions of psoriasis include well‐demarcated red plaques, with variable degrees of silvery thickening, and surface scale, particularly on the scalp, extensor aspects (backs of the elbows, fronts of the knees) of the limbs, and the trunk. Psoriatic arthritis, pustular psoriasis (a subtype of psoriasis with lesions containing purulent materials), or erythrodermic psoriasis (a subtype of psoriasis that affects nearly all body sites) may also be present. Among the various subtypes, psoriasis vulgaris is the most common form and accounts for more than 80% of psoriasis cases (<a href="./references#CD009481-bbs2-0054" title="LebwohlM . Psoriasis. Lancet2003;361(9364):1197‐204. [MEDLINE: 12686053] ">Lebwohl 2003</a>). The characteristic pathological changes of psoriasis present with hyperkeratosis (thickening of the stratum corneum, which is usually associated with an abnormality of the keratin and an increase of the granular layer), hyperplasia (increase in the number of cells) of the epidermis, inflammatory cell infiltration into the dermis and epidermis, and dilatation of dermal capillaries (dilated small blood vessels in the dermis). The diagnosis of psoriasis is mainly based on clinical features, and pathological changes are usually helpful to distinguish psoriasis from other diseases with a similar appearance. </p> </section> <section id="CD009481-sec-0033"> <h4 class="title">Cause</h4> <p>The exact cause of psoriasis remains unclear. However, psoriasis appears to be a disorder of immune function (specifically involving the T set of lymphocytes), which causes an accelerated rate of cell turnover in the epidermal layer of the skin (<a href="./references#CD009481-bbs2-0043" title="GriffithsCE , VoorheesJJ . Psoriasis, T cells and autoimmunity. Journal of the Royal Society of Medicine1996;89(6):315‐9. [MEDLINE: 8758188] ">Griffiths 1996</a>). People seem to have a strong genetic predisposition to develop the condition. Certain medications (such as lithium, beta blockers, antimalarial drugs, and nonsteroidal anti‐inflammatory drugs) and infections are thought to be possible triggers. </p> </section> <section id="CD009481-sec-0034"> <h4 class="title">Impact</h4> <p>Although psoriasis is rarely life‐threatening, the effect on a person's quality of life (QOL) can be profound, with a damaging effect on their self‐esteem, due to the long‐term nature of the disease, the persistent itching or pain of the skin, and the stigmatising effect of a disfiguring condition (<a href="./references#CD009481-bbs2-0035" title="DeKorteJ , SprangersMA , MombersFM , BosJD . Quality of life in patients with psoriasis: a systematic literature review. Journal of Investigative Dermatology Symposium2004;9(2):140‐7. [EMBASE: 2004161605] ">De Korte 2004</a>). It also seems to be associated with a significantly increased risk of cardiovascular disease (<a href="./references#CD009481-bbs2-0040" title="GelfandJM , NeimannAL , ShinDB , WangX , MargolisDJ , TroxelAB . Risk of myocardial infarction in patients with psoriasis. JAMA2006;296(14):1735‐41. [MEDLINE: 17032986] ">Gelfand 2006</a>) and a variety of malignant diseases (<a href="./references#CD009481-bbs2-0029" title="BoffettaP , GridleyG , LindelofB . Cancer risk in a population‐based cohort of patients hospitalized for psoriasis in Sweden. Journal of Investigative Dermatology2001;117(6):1531‐7. [MEDLINE: 11886519] ">Boffetta 2001</a>; <a href="./references#CD009481-bbs2-0039" title="GelfandJM , BerlinJ , VanVoorheesA , MargolisDJ . Lymphoma rates are low but increased in patients with psoriasis: results from a population‐based cohort study in the United Kingdom. Archives of Dermatology2003;139(11):1425‐9. [MEDLINE: 14623702] ">Gelfand 2003</a>; <a href="./references#CD009481-bbs2-0044" title="Hannuksela‐SvahnA , PukkalaE , LaaraE , PoikolainenK , KarvonenJ . Psoriasis, its treatment, and cancer in a cohort of Finnish patients. Journal of Investigative Dermatology2000;114(3):587‐90. [MEDLINE: 10692122] ">Hannuksela‐Svahn 2000</a>). </p> </section> </section> <section id="CD009481-sec-0035"> <h3 class="title" id="CD009481-sec-0035">Description of the intervention</h3> <p>Management of psoriasis should depend upon a number of factors: These include the severity of the disease, associated diseases (comorbidities), education about the chronic nature of the disease, and realistic expectations about the effect of treatments, as well as the use of medication. Complete clearance of psoriasis may be unrealistic, so the main aim of treatment is to reduce disease activity with minimal side‐effects. </p> <p>Interventions include topical therapy, ultraviolet light (phototherapy), systemic agents, and biological treatments. Those mildly affected can generally be treated adequately with topical medication, but 10% to 20% of those with moderate‐to‐severe psoriasis often depend upon phototherapy, systemic treatment, or combination therapy to achieve and sustain disease remission (<a href="./references#CD009481-bbs2-0050" title="JensenP , SkovL , ZachariaeC . Systemic combination treatment for psoriasis: a review. Acta Dermato‐Venereologica2010;90(4):341‐9. [MEDLINE: 20574597] ">Jensen 2010</a>). </p> <p>Phototherapy is an essential therapeutic option for people with psoriasis and has been used for more than 75 years. The most commonly used types of phototherapy are photochemotherapy using psoralen ultraviolet A (PUVA) and ultraviolet B (UVB) therapy. </p> <p>Therapy with PUVA is administered by the use of a photosensitiser prior to exposure to the phototherapy. The photosensitiser, psoralen, is administered either orally, or in bath water, or as a cream (or a gel) before exposure to long wavelength (320 to 400 nm) ultraviolet A (UVA) radiation. In consequence, PUVA is divided into oral PUVA, bath PUVA, and topical PUVA. With oral PUVA, different psoralens may be applied, such as 8‐methoxypsoralen (8‐MOP) and 5‐methoxypsoralen (5‐MOP). The psoralen 8‐MOP is the only available orally prescribed psoralen in the United States; it takes about one to three hours to reach peak concentration in the skin, so is usually administered at least two hours before UV irradiation. The most common side‐effect of PUVA is nausea that develops shortly after ingestion. Many people withdraw from PUVA therapy because of severe nausea. For those who cannot tolerate 8‐MOP, 5‐MOP is an alternative choice, which is more commonly used in Europe (<a href="./references#CD009481-bbs2-0031" title="Braun FalconO , PlewigG , WolffHH , BurgdorfWHC . Physical methods of therapy. In: Braun FalconO , PlewigG , WolffHH editor(s). Dermatology. Berlin: Springer‐Verlag, 2000:1767‐80. ">Braun 2000</a>; <a href="./references#CD009481-bbs2-0050" title="JensenP , SkovL , ZachariaeC . Systemic combination treatment for psoriasis: a review. Acta Dermato‐Venereologica2010;90(4):341‐9. [MEDLINE: 20574597] ">Jensen 2010</a>; <a href="./references#CD009481-bbs2-0057" title="MenterA , KormanNJ , ElmetsCA , FeldmanSR , GelfandJM , GordonKB , et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology2010;62(1):114‐35. [MEDLINE: 19811850] ">Menter 2010</a>). Trimethylpsoralen, which is used for bath PUVA, is largely used in Scandinavia, whereas 8‐MOP in a hydrophilic water or oil emulsion is used for topical PUVA (<a href="./references#CD009481-bbs2-0050" title="JensenP , SkovL , ZachariaeC . Systemic combination treatment for psoriasis: a review. Acta Dermato‐Venereologica2010;90(4):341‐9. [MEDLINE: 20574597] ">Jensen 2010</a>; <a href="./references#CD009481-bbs2-0057" title="MenterA , KormanNJ , ElmetsCA , FeldmanSR , GelfandJM , GordonKB , et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology2010;62(1):114‐35. [MEDLINE: 19811850] ">Menter 2010</a>). </p> <p>Therapy with PUVA has been proven to be effective for most forms of psoriasis and induces complete or partial remission in 79% to 90% of those with psoriasis (<a href="./references#CD009481-bbs2-0034" title="DeGruijlFR . Long‐term side effects and carcinogenesis risk in UVB therapy. In: HonigsmannH , JoriG , YoungAR editor(s). The Fundamental Bases of Photo‐therapy. Milan, Italy: OEMF, 1996:153‐70. ">De Gruijl 1996</a>; <a href="./references#CD009481-bbs2-0053" title="LauharantaJ . Photochemotherapy. Clinics in Dermatology1997;15(5):769‐80. [MEDLINE: 9313975] ">Lauharanta 1997</a>; <a href="./references#CD009481-bbs2-0059" title="MorisonWL , BaughmanRD , DayRM , ForbesPD , HoenigsmannH , KruegerGG , et al. Consensus workshop on the toxic effects of long‐term PUVA therapy. Archives of Dermatology1998;134(5):595‐8. [MEDLINE: 9606329] ">Morison 1998</a>). Unfortunately, current evidence shows a clear correlation between cumulative PUVA exposure and an increased risk of skin cancer and premature ageing of the skin (<a href="./references#CD009481-bbs2-0053" title="LauharantaJ . Photochemotherapy. Clinics in Dermatology1997;15(5):769‐80. [MEDLINE: 9313975] ">Lauharanta 1997</a>; <a href="./references#CD009481-bbs2-0056" title="LoweNJ , ChizhevskyV , GabrielH . Photo(chemo)therapy: general principles. Clinics in Dermatology1997;15(5):745‐52. [EMBASE: 1997295624] ">Lowe 1997</a>; <a href="./references#CD009481-bbs2-0069" title="SternRS , LangeR . Non‐melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. Journal of Investigative Dermatology1988;91(2):120‐4. [EMBASE: 1988194616] ">Stern 1988</a>). Therefore, the British Association of Dermatologists' guideline on biological interventions for psoriasis recommended that PUVA should be limited to 150 lifetime treatments, to decrease the risk of skin cancer (<a href="./references#CD009481-bbs2-0068" title="SmithCH , AnsteyAV , BarkerJN , BurdenAD , ChalmersRJ , ChandlerDA , et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology2009;161(5):987‐1019. [MEDLINE: 19857207] ">Smith 2009</a>). However, a combined analysis of two cohort studies with 944 participants treated with bath PUVA "found no increase in the risk of squamous cell carcinoma after a mean follow‐up of 14.7 years", suggesting that bath PUVA is possibly safer than oral PUVA (<a href="./references#CD009481-bbs2-0060" title="NaldiL . Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clinics in Dermatology2010;28(1):88‐92. [MEDLINE: 20082957] ">Naldi 2010</a>). </p> <p>UVB (spectrum light 280 to 320 nm) has been used to treat psoriasis for at least 90 years (<a href="./references#CD009481-bbs2-0022" title="AndersonTF , WaldingerTP , VoorheesJJ . UV‐B phototherapy. An overview. Archives of Dermatology1984;120(11):1502‐7. [MEDLINE: 6388509] ">Anderson 1984</a>). There are several types of UVB radiation in clinical practice:  </p> <p> <ol id="CD009481-list-0001"> <li> <p>conventional broad‐band UVB (BB‐UVB) lamps, which deliver radiation in the range of 280 to 320 nm; </p> </li> <li> <p>selective BB‐UVB, which has peaks at 305 to 325 nm; and</p> </li> <li> <p>narrow‐band UVB (NB‐UVB) lamps, which deliver almost exclusively 311 nm radiation (<a href="./references#CD009481-bbs2-0031" title="Braun FalconO , PlewigG , WolffHH , BurgdorfWHC . Physical methods of therapy. In: Braun FalconO , PlewigG , WolffHH editor(s). Dermatology. Berlin: Springer‐Verlag, 2000:1767‐80. ">Braun 2000</a>; <a href="./references#CD009481-bbs2-0049" title="IbbotsonSH , BilslandD , CoxNH , DaweRS , DiffeyB , EdwardsC , et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Brithish Journal of Dermatology2004; Vol. 151, issue 2:283‐97. [MEDLINE: 15327535] ">Ibbotson 2004</a>). </p> </li> </ol> </p> <p>Conventional BB‐UVB has been proven to cause the clearance of psoriasis within six weeks, but the use of it is limited by burning (<a href="./references#CD009481-bbs2-0028" title="BoerJ , SchothorstAA , SuurmondD . UV‐B phototherapy of psoriasis. Dermatologica1980;161(4):250‐8. [MEDLINE: 7409285] ">Boer 1980</a>). Selective BB‐UVB was also effective in treating psoriasis (<a href="./references#CD009481-bbs2-0062" title="ParrishJA , JaenickeKF . Action spectrum for phototherapy of psoriasis. Journal of Investigative Dermatology1981;76(5):359‐62. [MEDLINE: 7229428] ">Parrish 1981</a>). Phototherapy with NB‐UVB was developed in the 1980s. It is emitted through Philips TL01 lamps and consists of a subset of the UVB spectrum between 311 and 313 nm. A study conducted by Parrish and Jaenicke demonstrated that the peak action spectrum for clinical antipsoriatic efficacy was between 308 and 312 nm (<a href="./references#CD009481-bbs2-0037" title="FischerT . UV‐light treatment of psoriasis. Acta Dermato‐Venereologica1976;56(6):473‐9. [EMBASE: 0978025023] ">Fischer 1976</a>; <a href="./references#CD009481-bbs2-0062" title="ParrishJA , JaenickeKF . Action spectrum for phototherapy of psoriasis. Journal of Investigative Dermatology1981;76(5):359‐62. [MEDLINE: 7229428] ">Parrish 1981</a>). In this way, NB‐UVB can theoretically achieve an optimal response while minimising the erythrogenic (redness of the skin) response to non‐therapeutic wavelengths. In fact, several small‐scale clinical studies (<a href="./references#CD009481-bbs2-0015" title="CovenTR , BurackLH , GilleaudeauR , KeoghM , OzawaM , KruegerJG . Narrowband UV‐B produces superior clinical and histopathological resolution of moderate‐to‐severe psoriasis in patients compared with broadband UV‐B. Archives of Dermatology1997;133(12):1514‐22. [MEDLINE: 9420535] ">Coven 1997</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>; <a href="./references#CD009481-bbs2-0071" title="vanWeeldenH , De LaFailleHB , YoungE , van derLeunJC . A new development in UVB phototherapy of psoriasis. British Journal of Dermatology1988;119(1):11‐9. [MEDLINE: 3408653] ">van Weelden 1988</a>; <a href="./references#CD009481-bbs2-0072" title="WaltersIB , BurackLH , CovenTR , GilleaudeauP , KruegerJG . Suberythemogenic narrow‐band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. Journall of American Academic Dermatology1999;40(6 Pt 1):893‐900. [MEDLINE: 10365919] ">Walters 1999</a>) have shown an improved response of psoriasis to NB‐UVB compared with conventional BB‐UVB. </p> <p>There is controversy regarding the risk of skin cancer with NB‐UVB. <a href="./references#CD009481-bbs2-0074" title="YoungAR . Carcinogenicity of UVB phototherapy assessed. Lancet1995;345(8962):1431‐2. [DOI: 10.1016/S0140‐6736(95)92617‐8] ">Young 1995</a> summarised data from murine studies and reported NB‐UVB might be two to three times more carcinogenic per minimal erythema dose (MED) than conventional BB‐UVB. However, one systematic review (<a href="./references#CD009481-bbs2-0063" title="Pasker‐de JongPC , WielinkG , van derValkPG , van derWiltGJ . Treatment with UV‐B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Archives of Dermatology1999;135(7):834‐40. [MEDLINE: 10411159] ">Pasker‐de 1999</a>) estimated that "the excess annual risk of non‐melanoma skin cancer associated with UVB was likely to be less than 2%". Another systematic review found that UVB did not increase the risk of skin cancer during about 25 years' follow up (<a href="./references#CD009481-bbs2-0055" title="LeeE , KooJ , BergerT . UVB phototherapy and skin cancer risk: a review of the literature. International Journal of Dermatology2005;44(5):355‐60. [MEDLINE: 15869531] ">Lee 2005</a>). Likewise, no increased risk of cancer was identified in 3867 people treated by NB‐UVB in Scotland (<a href="./references#CD009481-bbs2-0045" title="HearnRM , KerrAC , RahimKF , FergusonJ , DaweRS . Incidence of skin cancers in 3867 patients treated with narrow‐band ultraviolet B phototherapy. British Journal of Dermatology2008;159(4):931‐5. [MEDLINE: 18834483] ">Hearn 2008</a>). Most recently, <a href="./references#CD009481-bbs2-0023" title="ArchierE , DevauxS , CastelaE , GalliniA , AubinF , LeMaitreM , et al. Carcinogenic risks of psoralen UV‐A therapy and narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 3):22‐31. [MEDLINE: 22512677] ">Archier 2012</a> found a lack of robust evidence of the carcinogenic risk of NB‐UVB because of limited prospective studies. </p> <p>Sometimes UVB or PUVA is combined with retinoids (e.g. etretinate and acitretin) to treat psoriasis. Retinoids have been established as an effective systemic therapy for psoriasis since the 1970s. They can be used as monotherapy or combined at low doses with UVB or PUVA for treating psoriasis. Etretinate was widely used initially; however, acitretin, the free acid of etretinate and its active metabolite, has replaced etretinate for treating psoriasis because of its more favourable pharmacokinetic profile (<a href="./references#CD009481-bbs2-0066" title="SauratJH . Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. Journal of the American Acadmy Dermatology1999;41(3 Pt 2):s2‐6. [MEDLINE: 10459139] ">Saurat 1999</a>). Generally, retinoids combined with NB‐UVB or PUVA are abbreviated as re‐NB‐UVB or re‐PUVA, respectively. </p> </section> <section id="CD009481-sec-0036"> <h3 class="title" id="CD009481-sec-0036">How the intervention might work</h3> <p>It has been found that UV exposure can affect cell signalling, favour development of T‐helper 2 (Th2) immune responses, and reduce both the number and function of antigen‐presenting Langerhans cells (<a href="./references#CD009481-bbs2-0075" title="ZanolliMD , CamisaC , FeldmanS , GulliverW , MenterA . Psoriasis: the high notes on current treatment. Program of the American Academy of Dermatology. Nashville, TN, August 5, 2000. ">Zanolli 2000</a>). </p> <p>Ultraviolet light in the UVA part of the spectrum is successfully used in the treatment of psoriasis, based on its ability to reduce mast cells and induce type I collagenase activity. Psoralen is used as a photosensitiser in PUVA therapy. Once psoralen is activated by UVA, "it crosslinks DNA strands, preventing replication of keratinocytes and inducing the death of activated T‐cells in the skin" (<a href="./references#CD009481-bbs2-0033" title="CovenTR , WaltersIB , CardinaleI , KruegerJG . PUVA‐induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatology, Photoimmunology &amp; Photomedicine1999;15(1):22‐7. [MEDLINE: 9990665] ">Coven 1999</a>). The significant effects of PUVA may be due to its immunosuppressive properties. The immunosuppressive mechanisms of PUVA mainly involve the following: decreasing the antigen‐presenting capacity of epidermal Langerhans cells and the numbers and functional activity of T‐helper cells and messenger RNA (mRNA) encoding for proinflammatory cytokines IL‐6, IL‐8, and TNF‐α. They may also involve inhibition of cell proliferation, reduction of the percentage of CD3+ peripheral T lymphocytes producing IFN‐gamma and IL‐2, and induction of an anergy (failure of response) of type 1 activity in peripheral lymphocytes (<a href="./references#CD009481-bbs2-0026" title="AubinF , HumbertP . Immunomodulation induced by psoralen plus ultraviolet A radiation. European Journal of Dermatology1998;8(3):212‐3. [MEDLINE: 9649704] ">Aubin 1998</a>; <a href="./references#CD009481-bbs2-0025" title="AshworthJ , KahanMC , BreathnachSM . PUVA therapy decreases HLA‐DR+ CDIa+ Langerhans cells and epidermal cell antigen‐presenting capacity in human skin, but flow cytometrically‐sorted residual HLA‐DR+ CDIa+ Langerhans cells exhibit normal alloantigen‐presenting function. British Journal of Dermatology1989;120(3):329‐39. [MEDLINE: 2469456] ">Ashworth 1989</a>; <a href="./references#CD009481-bbs2-0030" title="BorroniG , ZacconeC , VignatiG , FiettaA , GattiM , BrazzelliV , et al. Lymphopenia and decrease in the total number of circulating CD3+ and CD4+ T cells during 'long‐term' PUVA treatment for psoriasis. Dermatologica1991;183(1):10‐4. [MEDLINE: 1837524] ">Borroni 1991</a>; <a href="./references#CD009481-bbs2-0052" title="KozenitzkyL , DavidM , SredaiB , AlbeckM , ShohatB . Immunomodulatory effects of AS101 on interleukin‐2 production and T‐lymphocyte function of lymphocytes treated with psoralens and ultraviolet A. Photodermatology, Photoimmunology &amp; Photomedicine1992;9(1):24‐8. [MEDLINE: 1390119] ">Kozenitzky 1992</a>; <a href="./references#CD009481-bbs2-0061" title="NeunerP , CharvatB , KnoblerR , KirnbauerR , SchwarzA , LugerTA , et al. Cytokine release by peripheral blood mononuclear cells is affected by 8‐methoxypsoralen plus UV‐A. Photochemistry &amp; Photobiology1994;59(2):182‐8. [MEDLINE: 8165238] ">Neuner 1994</a>). </p> <p>The exact mechanism of action of UVB is not fully understood. The proposed mechanism may cause apoptosis (cell death) of lymphocytes and epidermal cells, as well as immunosuppressive and anti‐inflammatory effects (<a href="./references#CD009481-bbs2-0027" title="AufieroBM , TalwarH , YoungC , KrishnanM , HatfieldJS , LeeHK , et al. Narrow‐band UVB induces apoptosis in human keratinocytes. Journal of Photochemistry &amp; Photobiology2006;82(2):132‐9. [MEDLINE: 16309917] ">Aufiero 2006</a>). It has been demonstrated that the peak action spectrum for clinical efficacy is between 308 and 312 nm, while the maximal erythrogenic response occurs around 297 nm (<a href="./references#CD009481-bbs2-0037" title="FischerT . UV‐light treatment of psoriasis. Acta Dermato‐Venereologica1976;56(6):473‐9. [EMBASE: 0978025023] ">Fischer 1976</a>; <a href="./references#CD009481-bbs2-0062" title="ParrishJA , JaenickeKF . Action spectrum for phototherapy of psoriasis. Journal of Investigative Dermatology1981;76(5):359‐62. [MEDLINE: 7229428] ">Parrish 1981</a>). With NB‐UVB, because the peak spectrum is at 311 nm, significant antipsoriatic efficacy can be achieved with a limited erythrogenic response. </p> <p>The mechanism of the therapeutic effect of retinoids when combined with UVB or PUVA is also not yet fully understood. Pretreatment with retinoids can reduce "both desquamation and infiltration of psoriatic plaques", and in consequence might raise "the possibility of increased penetration of ultraviolet light" (<a href="./references#CD009481-bbs2-0050" title="JensenP , SkovL , ZachariaeC . Systemic combination treatment for psoriasis: a review. Acta Dermato‐Venereologica2010;90(4):341‐9. [MEDLINE: 20574597] ">Jensen 2010</a>). </p> </section> <section id="CD009481-sec-0037"> <h3 class="title" id="CD009481-sec-0037">Why it is important to do this review</h3> <p>There have been many studies, of variable methodological quality, comparing the efficacy of different types of phototherapy. Some indicate that PUVA is more effective than BB‐UVB radiation (<a href="./references#CD009481-bbs2-0032" title="BrennerW , JaschkeE , HonigsmannH . UV‐B phototherapy in psoriasis [UV‐B‐Phototherapie der Psoriasis]. Zeitschrift fur Hautkrankheiten1983;58(15):1113‐24. [MEDLINE: 6636924] ">Brenner 1983</a>; <a href="./references#CD009481-bbs2-0014" title="BoerJ , HermansJ , SchothorstAA , SuurmondD . Comparison of phototherapy (UV‐B) and photochemotherapy (PUVA) for clearing and maintenance therapy of psoriasis. Archives of Dermatology1984;120(1):52‐7. [MEDLINE: 6691715] ">Boer 1984</a>; <a href="./references#CD009481-bbs2-0048" title="HonigsmannH , FritschP , JaschkeE . UV‐therapy of psoriasis. Half‐side comparison between oral photochemotherapy (PUVA) and selective UV‐phototherapy (SUP) [UV‐Therapie der Psoriasis Halbseitenvergleich zwischen oraler Photochoemotherapie (PUVA) und selektiver UV‐Phototherapie (SUP)]. Zeitschrift fur Hautkrankheiten1977;52(21):1078‐82. [MEDLINE: 930225] ">Honigsmann 1977</a>; <a href="./references#CD009481-bbs2-0058" title="MorisonWL . Combination of methoxsalen and ultraviolet B (UVB) versus UVB radiation alone in treatment of psoriasis: a bilateral comparison study. Photodermatology, Photoimmunology &amp; Photomedicine1995;11(1):6‐8. [MEDLINE: 7654566] ">Morison 1995</a>); others demonstrate that NB‐UVB provides faster clearing of psoriasis, less burning reactions, and longer periods of remission than BB‐UVB phototherapy (<a href="./references#CD009481-bbs2-0015" title="CovenTR , BurackLH , GilleaudeauR , KeoghM , OzawaM , KruegerJG . Narrowband UV‐B produces superior clinical and histopathological resolution of moderate‐to‐severe psoriasis in patients compared with broadband UV‐B. Archives of Dermatology1997;133(12):1514‐22. [MEDLINE: 9420535] ">Coven 1997</a>; <a href="./references#CD009481-bbs2-0042" title="GreenC , FergusonJ , LakshmipathiT , JohnsonBE . 311 nm UVB phototherapy‐‐an effective treatment for psoriasis. British Journal of Dermatology1988;119(6):691‐6. [MEDLINE: 3203066] ">Green 1988</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>). NB‐UVB is also more convenient because no exogenous photosensitiser is needed before phototherapy. Recently, while some authors have claimed that NB‐UVB therapy has similar efficacy to PUVA (<a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>), other authors (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0070" title="TahirR , MujtabaG . Comparative efficacy of psoralen ‐ UVA photochemotherapy versus narrow band UVB phototherapy in the treatment of psoriasis. Journal of the College of Physicians &amp; Surgeons ‐ Pakistan2004;14(10):593‐5. [MEDLINE: 15456547] ">Tahir 2004</a>) have found different results. </p> <p>No systematic review has been conducted to summarise the evidence of the effects of NB‐UVB phototherapy compared with BB‐UVB or PUVA photochemotherapy for psoriasis. Therefore, we aimed to summarise results from randomised controlled trials (RCTs) to provide reliable evidence for clinicians and for those with psoriasis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009481-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009481-sec-0038"></div> <p>To assess the effects of narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen ultraviolet A photochemotherapy for psoriasis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009481-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009481-sec-0039"></div> <section id="CD009481-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009481-sec-0041"> <h4 class="title">Types of studies</h4> <p>We included any RCT involving NB‐UVB phototherapy versus BB‐UVB or PUVA photochemotherapy for psoriasis. We excluded quasi‐randomised trials. </p> </section> <section id="CD009481-sec-0042"> <h4 class="title">Types of participants</h4> <p>We included any individual with a diagnosis of any type of psoriasis, regardless of age, race, gender, or the severity of their lesions. </p> </section> <section id="CD009481-sec-0043"> <h4 class="title">Types of interventions</h4> <p>Any NB‐UVB phototherapy compared with BB‐UVB or PUVA photochemotherapy, either as a single or combination therapy. The following comparisons were performed: </p> <p> <ul id="CD009481-list-0002"> <li> <p>NB‐UVB versus oral PUVA;</p> </li> <li> <p>NB‐UVB versus bath PUVA;</p> </li> <li> <p>NB‐UVB versus topical PUVA;</p> </li> <li> <p>NB‐UVB combined with retinoids (re‐NB‐UVB) versus PUVA combined with retinoids (re‐PUVA);</p> </li> <li> <p>NB‐UVB versus selective BB‐UVB;</p> </li> <li> <p>NB‐UVB versus conventional BB‐UVB; and</p> </li> <li> <p>NB‐UVB combined with dithranol versus BB‐UVB combined with dithranol.</p> </li> </ul> </p> </section> <section id="CD009481-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD009481-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009481-list-0003"> <li> <p>Participant‐rated global improvement.</p> </li> <li> <p>Percentage of participants reaching Psoriasis Area and Severity Index (PASI) 75 (which meant equal to or more than 75% reduction in PASI score). </p> </li> <li> <p>Withdrawal due to side‐effects.</p> </li> <li> <p>Clearance rate. (Clearance was defined as no lesions of psoriasis or minimal residual activity (MRA)). </p> </li> </ol> </p> </section> <section id="CD009481-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009481-list-0004"> <li> <p>The Physician's Global Evaluation score.</p> </li> <li> <p>Dermatology Life Quality Index (DLQI).</p> </li> <li> <p>Number of treatments to clearance.</p> </li> <li> <p>Cumulative UV dose to clearance.</p> </li> <li> <p>Time to clearance.</p> </li> <li> <p>Clearance lasting six months.</p> </li> <li> <p>PASI score reduction (before and after treatment).</p> </li> <li> <p>Time to PASI 75.</p> </li> <li> <p>Relapse rate.</p> </li> <li> <p>Duration of remission.</p> </li> <li> <p>Withdrawal due to poor response.</p> </li> <li> <p>Clinical improvement.</p> </li> <li> <p>Reduction of peripheral T cells.</p> </li> <li> <p>Tolerability.</p> </li> <li> <p>Adverse events.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009481-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD009481-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 8 August 2013:</p> <p> <ul id="CD009481-list-0005"> <li> <p>the Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD009481-sec-0171">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 7, 2013, in <i>The Cochrane Library</i> using the search strategy in <a href="./appendices#CD009481-sec-0172">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via OVID (from 1946) using the strategy in <a href="./appendices#CD009481-sec-0173">Appendix 3</a>; and </p> </li> <li> <p>EMBASE via OVID (from 1974) using the strategy in <a href="./appendices#CD009481-sec-0174">Appendix 4</a>. </p> </li> </ul> </p> <p>We searched the following databases up to 27 November 2012:</p> <p> <ul id="CD009481-list-0006"> <li> <p>CNKI (China National Knowledge Infrastructure, from 1974) using the strategy in <a href="./appendices#CD009481-sec-0175">Appendix 5</a>; and </p> </li> <li> <p>CBM (Chinese Biomedical Database, from 1978) using the strategy in <a href="./appendices#CD009481-sec-0176">Appendix 6</a>. </p> </li> </ul> </p> </section> <section id="CD009481-sec-0049"> <h4 class="title">Searching other resources</h4> <section id="CD009481-sec-0050"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers using the strategy in <a href="./appendices#CD009481-sec-0177">Appendix 7</a> on 27 November 2012: </p> <p> <ul id="CD009481-list-0007"> <li> <p>The metaRegister of Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>). </p> </li> <li> <p>The US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry platform (<a href="http://www.who.int/ trialsearch" target="_blank">www.who.int/ trialsearch</a>). </p> </li> <li> <p>Chinese Clinical Trial Registry (<a href="http://www.chictr.org" target="_blank">www.chictr.org</a>). </p> </li> </ul> </p> </section> <section id="CD009481-sec-0051"> <h5 class="title">Reference lists</h5> <p>We scanned the references of all included trials and relevant systematic reviews or meta‐analyses to identify further relevant trials. </p> </section> <section id="CD009481-sec-0052"> <h5 class="title">Conference proceedings</h5> <p>We handsearched abstracts from the following dermatological conference proceedings for further RCTs up to November 2012: </p> <p> <ul id="CD009481-list-0008"> <li> <p>World Congress of Dermatology (from 1980);</p> </li> <li> <p>International Congress of Dermatology (from 1980); and</p> </li> <li> <p>European Academy of Dermatology and Venereology (from 1980).</p> </li> </ul> </p> </section> <section id="CD009481-sec-0053"> <h5 class="title">Unpublished literature</h5> <p>We searched the OpenGrey database (<a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu</a>) for grey literature using the search strategy in <a href="./appendices#CD009481-sec-0177">Appendix 7</a>. </p> <p>We were not able to contact authors to obtain unpublished trials, as we had planned, because of time and resource constraints. </p> </section> <section id="CD009481-sec-0054"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of the target interventions. We considered data on adverse effects from the included studies we identified. </p> </section> </section> </section> <section id="CD009481-sec-0055"> <h3 class="title" id="CD009481-sec-0055">Data collection and analysis</h3> <section id="CD009481-sec-0056"> <h4 class="title">Selection of studies</h4> <p>Two review authors (XMC and YC) independently scanned the titles and abstracts of all articles identified from the searches according to our inclusion and exclusion criteria. For all initially selected articles, we obtained the full text; thereafter, two review authors (XMC and MY) independently assessed them to see whether they were eligible for inclusion. </p> <p>We listed the studies that were excluded and the reasons for their exclusion in the review. During this process, we resolved discrepancies by discussion with MZ, who acted as an arbitrator. </p> </section> <section id="CD009481-sec-0057"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (XMC and MY) extracted the data from the included studies separately. We documented the process of resolving discrepancies in this review. We used the standard data extraction form recommended by the Cochrane Skin Group and recorded information about the following areas: </p> <p> <ul id="CD009481-list-0009"> <li> <p>general information (authors, title, source, year of publication, language of publication, trial numbers); </p> </li> <li> <p>trial characteristics (design; manner of recruitment; inclusion and exclusion criteria; duration of intervention period; reason for, and number of, dropouts and withdrawals); </p> </li> <li> <p>participants (baseline characteristics of participants in all groups, such as gender, age, psoriasis severity, and baseline health‐related quality of life (HRQoL) scores); </p> </li> <li> <p>interventions (any intervention in both study and control groups); and</p> </li> <li> <p>outcomes (specific outcomes reported, assessment instrument used, adverse events).</p> </li> </ul> </p> <p>We tried to contact trial authors for more information where necessary. One of us (MY) checked and entered the data into Review Manager (RevMan). Another author (XMC) double‐checked the data. We resolved disagreements by discussion within the review team. </p> </section> <section id="CD009481-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (XMC and MY) independently assessed the methodological quality of the included studies. We settled discrepancies by discussion within the review team. We used The Cochrane Collaboration's tool for assessing risk of bias, which forms part of the '<a href="./references#CD009481-sec-0188" title="">Characteristics of included studies</a>' tables (<a href="./references#CD009481-bbs2-0046" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and we addressed the following issues: </p> <p>(a) was there adequate sequence generation?;<br/> (b) was allocation adequately concealed?;<br/> (c) was knowledge of the allocated interventions adequately prevented during the study?;<br/> (d) were incomplete outcome data adequately addressed?;<br/> (e) were reports of the study free of suggestion of selective outcome reporting?; and<br/> (f) was the study apparently free of other problems that could put it at a risk of bias? </p> <p>We documented our judgements for each item and the reasons for our judgements in the 'Risk of bias' table for each included study within the review. </p> <p>Where necessary, we attempted to contact trial authors for more information.</p> </section> <section id="CD009481-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>According to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009481-bbs2-0046" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), we defined measures of treatment effects as follows. </p> <section id="CD009481-sec-0060"> <h5 class="title">Dichotomous data</h5> <p>We presented dichotomous outcomes as risk ratios (RR) with 95% confidence intervals (CIs) for individual trials. We discussed the main outcomes of each study and, if possible, pooled feasible data. </p> </section> <section id="CD009481-sec-0061"> <h5 class="title">Continuous data</h5> <p>For continuous variables, such as the score of life quality index, we used the mean difference and 95% CI, unless different scales were used in the trials, in which case we used a standardised mean difference (SMD) and 95% CI to summarise the data. </p> </section> </section> <section id="CD009481-sec-0062"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009481-sec-0063"> <h5 class="title">Simple parallel RCTs</h5> <p>The unit of analysis was individual participants.</p> </section> <section id="CD009481-sec-0064"> <h5 class="title">Cluster RCTs</h5> <p>In the protocol, we stated that if we identified cluster RCTs, we would try to re‐analyse these trials by calculating the effective sample sizes according to the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009481-bbs2-0046" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and if possible, we would calculate an estimate of the intracluster coefficient (ICC), using external estimates obtained from similar trials. We would not pool data from cluster RCTs with those from parallel RCTs. However, we found no eligible cluster trials. </p> </section> <section id="CD009481-sec-0065"> <h5 class="title">Cross‐over RCTs</h5> <p>In the protocol, we stated that if we identified cross‐over RCTs, we would only extract and analyse data from the first period (<a href="./references#CD009481-bbs2-0046" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We would not pool data from cross‐over RCTs with those from parallel RCTs. However, we found no eligible cross‐over RCTs. </p> </section> <section id="CD009481-sec-0066"> <h5 class="title">Multiple intervention groups within a trial</h5> <p>No relevant trial was included in this review. If we identify relevant trials for future updates of this review, we will deal with them as we planned in the published protocol. </p> </section> <section id="CD009481-sec-0067"> <h5 class="title">Multiple body parts receiving the same intervention</h5> <p>No relevant trial was included in this review. If we identify relevant trials for future updates of this review, we will deal with them as we planned in the published protocol. </p> </section> <section id="CD009481-sec-0068"> <h5 class="title">Multiple body parts receiving different interventions</h5> <p>In some included trials, the left and right sides of the body were randomly allocated into different groups and to receive different interventions. In this regard, the unit of analysis was half‐body. </p> </section> </section> <section id="CD009481-sec-0069"> <h4 class="title">Dealing with missing data</h4> <p>First, we attempted to contact the trial authors to get more information where necessary. If this did not succeed, we considered participants with missing outcomes as treatment failures for dichotomous outcomes. In the case of participant dropout, we conducted intention‐to‐treat (ITT) analyses for primary outcomes. </p> <p>For continuous outcomes, we only extracted and analysed the available data. In addition, we explored the impact of missing data on the treatment effect by using sensitivity analyses, where possible. In future updates, if there were missing continuous data, we would state the whole process of dealing with the missing data and its potential impact on the results of the review in the Discussion section of our review. </p> </section> <section id="CD009481-sec-0070"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated the level of clinical heterogeneity by comparing the differences between the trials in the administration of therapy, the type of comparators used, and the characteristics of the study population. If an appropriate level of clinical homogeneity existed, we analysed the level of statistical heterogeneity using the Chi² test on N‐1 degrees of freedom, with an alpha of 0.1 used for statistical significance and the I² statistic. I² statistic values of 25%, 50%, and 75% correspond to low, medium, and high levels of heterogeneity (<a href="./references#CD009481-bbs2-0046" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If heterogeneity existed, we attempted to probe the reasons for it and advised caution in the interpretation of our results. </p> </section> <section id="CD009481-sec-0071"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had identified sufficient RCTs, we would have used funnel plots to test for publication bias. However, we could not use funnel plots to test for publication bias, because for each outcome, there were insufficient studies to perform it (<a href="./references#CD009481-bbs2-0046" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009481-sec-0072"> <h4 class="title">Data synthesis</h4> <p>We pooled data using the random‐effects model, unless there were less than three trials without clinical heterogeneity ‐ in which case, we used the fixed‐effect model. If we identified substantial heterogeneity, we reported the results qualitatively. </p> </section> <section id="CD009481-sec-0073"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Because of insufficient information, we could only perform subgroup analysis to detect the potential heterogeneity induced by study design (e.g. some studies performed left‐right body comparisons, while others performed comparisons between participants) in some outcomes. </p> </section> <section id="CD009481-sec-0074"> <h4 class="title">Sensitivity analysis</h4> <p>In the protocol, we stated that we would perform sensitivity analyses, where possible, but we were unable to carry this out because of insufficient data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009481-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009481-sec-0075"></div> <section id="CD009481-sec-0076"> <h3 class="title">Description of studies</h3> <p>See the '<a href="./references#CD009481-sec-0188" title="">Characteristics of included studies</a>', '<a href="./references#CD009481-sec-0189" title="">Characteristics of excluded studies</a>', and '<a href="./references#CD009481-bbs1-0003" title="">Studies awaiting classification</a>' tables. </p> <section id="CD009481-sec-0077"> <h4 class="title">Results of the search</h4> <p>Our electronic search retrieved 1798 references excluding duplicates. After scanning the titles and abstracts, we identified 25 references as potentially relevant, which we retrieved in full text. Among these, 17 references referring to 13 RCTs met the inclusion criteria. One reference (<a href="./references#CD009481-bbs2-0021" title="NazariS , OzarmaganG , ErzenginD , AkarU . A randomized comparison of narrow‐band UVB phototherapy and PUVA photochemotherapy in the management of plaque‐type psoriasis [Psoriasiste PUVA ve dar bant UVB tedavilerinin klinik etkinliklerinin karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):103‐8. [EMBASE: 2006204570] ">Nazari 2005</a>) was published in Turkish, and we are waiting for a translation. It is listed in <a href="./references#CD009481-sec-0190" title="">Characteristics of studies awaiting classification</a>. We excluded the remaining seven references. We identified no further reports by screening the reference lists of all included RCTs, relevant systematic reviews or meta‐analyses, and dermatological conference proceedings. We present the screening process in <a href="#CD009481-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009481-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD009481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD009481-sec-0078"> <h4 class="title">Included studies</h4> <p>In this review, we included 13 RCTs, with a total of 662 participants. More information about these 13 studies (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) is available in the '<a href="./references#CD009481-sec-0188" title="">Characteristics of included studies</a>' tables. </p> <section id="CD009481-sec-0079"> <h5 class="title">Design</h5> <p>Some of the included RCTs (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) performed comparisons between participants, whereas others (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) performed within‐patient comparisons (left‐right body comparison). </p> </section> <section id="CD009481-sec-0080"> <h5 class="title">Sample sizes</h5> <p>With regard to the size of the individual trials, participant numbers ranged from 18 to 100. </p> </section> <section id="CD009481-sec-0081"> <h5 class="title">Setting</h5> <p>The included RCTs were published from 1989 to 2011. Five of them were conducted in the UK (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>); two, in Turkey (<a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>); the remaining RCTs were conducted in India (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>), Ireland (<a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>), Sweden (<a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>), Egypt (<a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>), Finland (<a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>), and Germany (<a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>), respectively. </p> </section> <section id="CD009481-sec-0082"> <h5 class="title">Participants</h5> <p>Most of the included studies recruited adults (≥18 years of age) except for two RCTs (<a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>), which recruited participants aged from 13 to 63 years and 17 to 66 years, respectively. In addition, another RCT (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>) did not report the age of the participants. </p> <p>Most of the included RCTs (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) focused on chronic plaque psoriasis (CPP), and one RCT (<a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>) paid attention to palmoplantar psoriasis (PPP), while the remaining RCTs (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) included people with different kinds of psoriasis. </p> </section> <section id="CD009481-sec-0083"> <h5 class="title">Interventions</h5> <p>The following comparisons were identified:</p> <p> <ul id="CD009481-list-0010"> <li> <p>NB‐UVB versus oral PUVA (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>); </p> </li> <li> <p>NB‐UVB versus bath PUVA (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>); </p> </li> <li> <p>NB‐UVB versus topical PUVA (<a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>); </p> </li> <li> <p>re‐NB‐UVB versus re‐PUVA (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>); </p> </li> <li> <p>NB‐UVB versus selective BB‐UVB (<a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>); </p> </li> <li> <p>NB‐UVB versus conventional BB‐UVB (<a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>); and </p> </li> <li> <p>NB‐UVB + dithranol versus conventional BB‐UVB + dithranol (<a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>). </p> </li> </ul> </p> <p>In most included trials, NB‐UVB was performed three times weekly, except in two trials (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>), which carried out NB‐UVB twice a week. In addition, BB‐UVB was conducted three to five times weekly (<a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>); bath PUVA, two (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>) or three (<a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>) times weekly; oral PUVA was performed two (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) or three (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>) times weekly; and topical PUVA was conducted three times weekly (<a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>). </p> </section> <section id="CD009481-sec-0084"> <h5 class="title">Outcomes</h5> <p>Outcome measurements were very variable. For example, some included RCTs reported "complete clearance" as their primary outcome, whereas others applied "minimal residual activity (MRA)" or clearance; some applied Psoriasis Area and Severity Index (PASI) score reduction to assess the improvement of psoriasis, whereas others presented the percentage of participants who achieved PASI 75 (which meant equal to or more than 75% reduction in PASI score). It was noteworthy that most of these outcomes were on the basis of judgement from clinicians and were subjective and relatively imprecise. Only one trial (<a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>) reported the tolerability of the treatment assessed by the participants themselves. Another trial (<a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) assessed the participants' QOL, which is often omitted in clinical practice. </p> </section> </section> <section id="CD009481-sec-0085"> <h4 class="title">Excluded studies</h4> <p>We excluded seven studies. Our reasons for exclusion are shown in the '<a href="./references#CD009481-sec-0189" title="">Characteristics of excluded studies</a>' tables. </p> </section> </section> <section id="CD009481-sec-0086"> <h3 class="title">Risk of bias in included studies</h3> <p>We applied The Cochrane Collaboration's tool for assessing risk of bias. <a href="#CD009481-fig-0002">Figure 2</a> and <a href="#CD009481-fig-0003">Figure 3</a> illustrate the overall risk of bias. </p> <div class="figure" id="CD009481-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: Review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD009481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: Review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <div class="figure" id="CD009481-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: Review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD009481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: Review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD009481-sec-0087"> <h4 class="title">Allocation</h4> <p>Randomisation and concealment of allocation are thought to be essential components of a RCT to minimise bias. All included trials were reported as "randomised"; however, in five of them (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>), no further methodological details were given, so we assessed these as having an 'unclear' risk of bias for this domain. In four of the included RCTs (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>), randomisation was conducted within participants; in other words, the left and right side of the participant's body were randomly allocated into different groups. </p> <p>Seven included RCTs (<a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) did not explicitly report whether allocation concealment was performed or not, so we assessed these as having an unclear risk of bias for this domain. Another RCT (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>) clearly stated that "the random allocation list was not concealed," so we assessed this as at a high risk of bias for this domain. </p> </section> <section id="CD009481-sec-0088"> <h4 class="title">Blinding</h4> <p>We evaluated blinding of participants and personnel and blinding of outcome assessment separately. We applied the former to check performance bias, whereas the latter was to check detection bias. Only one RCT (<a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) performed blinding of participants and personnel. The reason may be that different devices and therapy schemes are needed to perform different types of UV irradiation, and consequently, it is hard to mask phototherapists and participants. In addition, eight RCTs (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) performed blinding of the outcome assessment. </p> </section> <section id="CD009481-sec-0089"> <h4 class="title">Incomplete outcome data</h4> <p>We labelled 10 of the 13 included studies as 'low risk of bias' in this regard. In most of the included trials, the rate of dropouts was lower than 20%, and the reasons were clearly reported and the withdrawals distributed equally between the groups. To be more specific, the rate of discontinuation in the included studies ranged from 0% (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) to 36% (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>). It was less than 10% in five RCTs (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>), 10% to 20% in six RCTs (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>), and more than 20% in one RCT (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>). In <a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>, 16% of the participants discontinued the trial, and when assessing "time to relapse", only 57% of the participants were available for analysis. We assessed this study at 'high risk of bias'. One RCT (<a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>) did not report the rate of discontinuation, so we assessed this as unclear. </p> <p>An intention‐to‐treat (ITT) analysis is often recommended as the least biased way to estimate intervention effects in RCTs (<a href="./references#CD009481-bbs2-0046" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Three included RCTs (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>) applied ITT analyses. In <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>, 10 (36%) participants discontinued the study, which might have induced significant attrition bias. As a result, we labelled this trial as 'high risk of bias', although ITT analyses were applied. </p> </section> <section id="CD009481-sec-0090"> <h4 class="title">Selective reporting</h4> <p>Almost all included trials had no preliminarily published protocol or were not registered in any clinical trial database, except for one (<a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>). In five trials (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>), all outcomes described in their methods section were reported appropriately with statistical data in the results section, and in consequence, we labelled them as 'low risk of bias'. In two trials (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>), there was insufficient information to make a judgement. We labelled four RCTs (<a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) at 'high risk of bias' where some outcomes were not supported by statistical data. <a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a> did not report in their results section some outcomes described in their methods section, and in <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>, the authors reported mean and range in the main outcomes, but not P values or 95% CIs, so we labelled these two studies as at 'high risk of bias' for this domain. </p> </section> <section id="CD009481-sec-0091"> <h4 class="title">Other potential sources of bias</h4> <p>Five trials (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) conducted randomisation within participants, and as a result, withdrawal of one half‐body for any reason inevitably caused withdrawal of the other half. In addition, because each participant received both treatment regimens, the treatment to one side might have affected the other. These effects might have induced other potential biases. In the other eight trials, there was insufficient information to make a judgement. </p> </section> </section> <section id="CD009481-sec-0092"> <h3 class="title" id="CD009481-sec-0092">Effects of interventions</h3> <p>See: <a href="./full#CD009481-tbl-0001"><b>Summary of findings for the main comparison</b> NB‐UVB compared with oral PUVA for chronic plaque psoriasis</a>; <a href="./full#CD009481-tbl-0002"><b>Summary of findings 2</b> NB‐UVB compared with bath PUVA for chronic plaque psoriasis</a>; <a href="./full#CD009481-tbl-0003"><b>Summary of findings 3</b> NB‐UVB compared with topical PUVA for palmoplantar psoriasis</a>; <a href="./full#CD009481-tbl-0004"><b>Summary of findings 4</b> NB‐UVB plus retinoid compared with PUVA plus retinoid for chronic plaque or guttate psoriasis</a>; <a href="./full#CD009481-tbl-0005"><b>Summary of findings 5</b> NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis</a> </p> <p>We made the decision to move one of our prespecified secondary outcomes to primary outcome 4 and rename it 'clearance rate'. We also added further outcomes to our secondary outcomes. We have explained our reasoning for making this change to our published protocol in the <a href="#CD009481-sec-0185">Differences between protocol and review</a> section. </p> <p>Please read this section with the following summaries:</p> <p> <ul id="CD009481-list-0011"> <li> <p><a href="./full#CD009481-tbl-0001">summary of findings Table for the main comparison</a>: NB‐UVB compared with oral PUVA for chronic plaque psoriasis; </p> </li> <li> <p><a href="./full#CD009481-tbl-0002">summary of findings Table 2</a>: NB‐UVB compared with bath PUVA for chronic plaque psoriasis; </p> </li> <li> <p><a href="./full#CD009481-tbl-0003">summary of findings Table 3</a>: NB‐UVB compared with topical PUVA for palmoplantar psoriasis; </p> </li> <li> <p><a href="./full#CD009481-tbl-0004">summary of findings Table 4</a>: NB‐UVB plus retinoid compared with PUVA plus retinoid for chronic plaque or guttate psoriasis; and </p> </li> <li> <p><a href="./full#CD009481-tbl-0005">summary of findings Table 5</a>: NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis. </p> </li> </ul> </p> <section id="CD009481-sec-0093"> <h4 class="title">1. NB‐UVB compared with oral PUVA for chronic plaque psoriasis</h4> <section id="CD009481-sec-0094"> <h5 class="title">Primary outcomes</h5> <section id="CD009481-sec-0095"> <h6 class="title">1) Participant‐rated global improvement</h6> <p>No included RCTs addressed this outcome for this comparison.</p> </section> <section id="CD009481-sec-0096"> <h6 class="title">2) Percentage of participants reaching PASI 75</h6> <p>Only one trial (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>) reported the percentage of participants with chronic plaque psoriasis (CPP) who reached PASI 75. Seventeen of 21 (80.9%) participants in the NB‐UVB group compared with 18 of 22 (81.8%) participants in the oral PUVA group reached PASI 75; the difference was not statistically significant (RR 0.99, 95% CI 0.74 to 1.32; N = 43; <a href="./references#CD009481-fig-0004" title="">Analysis 1.1</a>). <a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a> did not perform ITT analysis. As mentioned in the <a href="#CD009481-sec-0039">Methods</a> section, we considered participants with missing outcomes as treatment failures for dichotomous outcomes and conducted ITT analysis. The result indicated that no significant difference was identified between NB‐UVB and oral PUVA groups (RR 0.91, 95% CI 0.63 to 1.32; N = 51; <a href="./references#CD009481-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD009481-sec-0097"> <h6 class="title">3) Withdrawal due to side‐effects</h6> <p>Pooled data from three trials (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) indicated that withdrawals due to adverse events were not significantly different between the NB‐UVB group and the oral PUVA group in participants with CPP (RR 0.69, 95% CI 0.19 to 2.43; N = 231; <a href="./references#CD009481-fig-0006" title="">Analysis 1.3</a>). The ITT analysis revealed a similar result (RR 0.71, 95% CI 0.20 to 2.54; N = 247; <a href="./references#CD009481-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD009481-sec-0098"> <h6 class="title">4) Clearance rate</h6> <p>Three trials (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) compared NB‐UVB to oral PUVA with respect to clearance rate in participants with CPP. Because we identified statistically significant heterogeneity between the three studies (I² statistic = 91%), we did not pool the data. Among them, <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a> did not perform ITT analysis, and the result showed that the clearance rate was 51.1% in the NB‐UVB group and 79.1% in the oral PUVA group (RR 0.65, 95% CI 0.47 to 0.89; N = 88; <a href="./references#CD009481-fig-0008" title="">Analysis 1.5</a>). We conducted ITT analysis using the data of <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a> and found a very similar result: The clearance rate was 48.9% in the NB‐UVB group and 73.9% in the oral PUVA group (RR 0.66, 95% CI 0.47 to 0.93; N = 93; <a href="./references#CD009481-fig-0009" title="">Analysis 1.6</a>). <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a> performed ITT analysis and found that the clearance rate was 62.7% in the NB‐UVB group and 83.7% in the oral PUVA group (RR 0.75, 95% CI 0.59 to 0.96; N = 100; <a href="./references#CD009481-fig-0009" title="">Analysis 1.6</a>). <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a> also performed ITT analysis; however, there was no significant difference between the NB‐UVB and the oral PUVA groups with respect to clearance rate (96.6% versus 96%; RR 1.01, 95% CI 0.91 to 1.12; N = 54; <a href="./references#CD009481-fig-0009" title="">Analysis 1.6</a>). </p> </section> </section> <section id="CD009481-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD009481-sec-0100"> <h6 class="title">1) The Physician's Global Evaluation score</h6> <p>No included RCTs addressed this outcome for this comparison.</p> </section> <section id="CD009481-sec-0101"> <h6 class="title">2) Dermatology Life Quality Index (DLQI)</h6> <p><a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a> reported DLQI as an outcome in participants with CPP, which is a simple practical tool for assessing the QOL of people with skin diseases (<a href="./references#CD009481-bbs2-0036" title="FinlayAY , KhanGK . Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clinical &amp; Experimental Dermatology1994;19:210‐6. [MEDLINE: 8033378] ">Finlay 1994</a>). The reduction of DLQI scores was statistically significantly greater in the oral PUVA group than in the NB‐UVB group (the Mann‐Whitney test, Z = ‐2.4, P = 0.02). In other words, the participants' QOL in the oral PUVA group was improved more than in the NB‐UVB group. </p> </section> <section id="CD009481-sec-0102"> <h6 class="title">3) Number of treatments to clearance</h6> <p>Three included trials (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) reported this outcome in participants with CPP. We could not perform meta‐analysis because of insufficient data. <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a> showed the median number of treatments to clearance was 25.3 for NB‐UVB and 16.7 for oral PUVA (P &lt; 0.001). <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a> reported the median number of treatments to clearance was 25.5 for NB‐UVB and 19 for oral PUVA (the Mann‐Whitney test, P = 0.03). <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a> found the median number of treatments to clearance was 28.5 for NB‐UVB and 17 for oral PUVA, and the difference was statistically significant (the Mann‐Whitney test, Z = ‐3.7, P &lt; 0.01). </p> </section> <section id="CD009481-sec-0103"> <h6 class="title">4) Cumulative UV dose to clearance</h6> <p>There is evidence that lower cumulative UV dose is relevant to lower risk of skin cancer (<a href="./references#CD009481-bbs2-0041" title="GodarDE , UrbachF , GasparroFP , van derLeunJC . UV doses of young adults. Photochem Photobiol2003;77(4):453‐7. ">Godar 2003</a>). In the study by <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>, in participants with CPP, the median cumulative UV dose to clearance was 35 J/cm² for NB‐UVB and 75.1 J/cm² for oral PUVA. However, the study authors did not clearly describe whether the difference between the two groups was statistically significant. </p> </section> <section id="CD009481-sec-0104"> <h6 class="title">5) Time to clearance</h6> <p>In the study by <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>, in people with CPP, the median time to clearance in the NB‐UVB group was 66 days, whereas it was 67 days in the oral PUVA group. The difference between the two groups did not reach statistical significance (P = 0.46). </p> </section> <section id="CD009481-sec-0105"> <h6 class="title">6) Clearance lasting six months</h6> <p>In the study by <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a> in people with CPP, more skin lesions in the oral PUVA group achieved clearance lasting six months, which was statistically significant compared with those in the NB‐UVB group (RR 0.51, 95% CI 0.28 to 0.94; N = 47; <a href="./references#CD009481-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD009481-sec-0106"> <h6 class="title">7) PASI score reduction (before and after treatment)</h6> <p>No included RCTs addressed this outcome for this comparison.</p> </section> <section id="CD009481-sec-0107"> <h6 class="title">8) Time to PASI 75</h6> <p>In the study by <a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>, in participants with CPP, the mean time to PASI 75 was 9.9 weeks in both NB‐UVB and oral PUVA groups (mean difference (MD) 0.00, 95% CI ‐2.03 to 2.03; N = 43; <a href="./references#CD009481-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD009481-sec-0108"> <h6 class="title">9) Relapse rate</h6> <p>Three included trials, which were conducted in participants with CPP, reported this outcome (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>). Pooled data showed that the lesions in 36 of 90 (40%) participants who received NB‐UVB compared with 31 of 82 (37.8%) participants who received oral PUVA group relapsed at six months after treatment completion, but the difference between groups did not reach statistical significance (RR 1.08, 95% CI 0.74 to 1.58; N = 162; <a href="./references#CD009481-fig-0012" title="">Analysis 1.9</a>). These studies defined relapse as 50% of the original extent of the lesions. </p> </section> <section id="CD009481-sec-0109"> <h6 class="title">10) Duration of remission</h6> <p>In the study by <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>, the median duration of remission for participants with CPP was 288.5 days in the NB‐UVB group and 231 days in the oral PUVA group; however, the difference between groups was not statistically significant (P = 0.40). The study did not explicitly define remission. </p> </section> <section id="CD009481-sec-0110"> <h6 class="title">11) Withdrawal due to poor response</h6> <p>In the study by <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>, in participants with CPP, withdrawals due to poor response were significantly more in the NB‐UVB group than in the oral PUVA group (29.4% versus 6%; RR 4.80, 95% CI 1.48 to 15.57; N = 100; <a href="./references#CD009481-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD009481-sec-0111"> <h6 class="title">12) Clinical improvement</h6> <p>No included RCTs addressed this secondary outcome for this comparison.</p> </section> <section id="CD009481-sec-0112"> <h6 class="title">13) Reduction of peripheral T cells</h6> <p>No included RCTs addressed this secondary outcome for this comparison.</p> </section> <section id="CD009481-sec-0113"> <h6 class="title">14) Tolerability</h6> <p>No included RCTs addressed this secondary outcome for this comparison.</p> </section> <section id="CD009481-sec-0114"> <h6 class="title">15) Adverse events</h6> <p>Four RCTs (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) addressed the following adverse events conducted in participants with CPP: erythema (in different degrees), pruritus, polymorphic light eruption (PMLE), nausea, and folliculitis (<a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>). They were generally slight and reversible. <a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a> indicated that the incidence of any adverse events was not significantly different between NB‐UVB and PUVA groups (RR 0.92, 95% CI 0.40 to 2.08; N = 43; <a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>, see Analysis 1.11.7). </p> <p>Pooled data from three trials (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) indicated that the incidence of erythema was comparable between NB‐UVB and oral PUVA groups (RR 0.99, 95% CI 0.47 to 2.09; N = 233; <a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>, see Analysis 1.11.1). Similarly, no significant difference was identified between NB‐UVB and oral PUVA groups with respect to grade one erythema (<a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; RR 0.93, 95% CI 0.68 to 1.26; N = 45; <a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>, see Analysis 1.11.5) and grade two erythema (<a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>; RR 0.48, 95% CI 0.13 to 1.79; N = 88; <a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>, see Analysis 1.11.6). </p> <p>Pooled data from two trials (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) showed the incidence of nausea was significantly lower in the NB‐UVB group than in the oral PUVA group (0% versus 12.3%; RR 0.12, 95% CI 0.02 to 0.94; N = 131; <a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>, see Analysis 1.11.2). </p> <p>Furthermore, <a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a> found that the incidence of pruritus was not significantly different between NB‐UVB and PUVA groups (23.8% versus 27.3%; RR 0.87, 95% CI 0.31 to 2.43; N = 43; <a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>, see Analysis 1.11.3), or between the NB‐UVB and PUVA groups with respect to PMLE (9% versus 9.5%; RR 1.05, 95% CI 0.16 to 6.77; N = 43; <a href="./references#CD009481-fig-0014" title="">Analysis 1.11</a>, see Analysis 1.11.4). </p> </section> </section> </section> <section id="CD009481-sec-0115"> <h4 class="title">2. NB‐UVB compared with bath PUVA for chronic plaque psoriasis</h4> <section id="CD009481-sec-0116"> <h5 class="title">Primary outcomes</h5> <p>Only one primary outcome was addressed for this comparison.</p> <section id="CD009481-sec-0117"> <h6 class="title">4) Clearance rate</h6> <p>Three trials (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>) compared NB‐UVB to bath PUVA in participants with CPP. Among them, <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a> and <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a> conducted left‐right body comparisons while <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a> conducted comparisons between participants. Pooled data from <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a> and <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a> indicated that no significant difference between the two groups were identified (RR 2.03, 95% CI 0.29 to 14.06; N = 35; <a href="./references#CD009481-fig-0015" title="">Analysis 2.1</a>). However, <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a> found that two of 16 participants (12.5%) in the NB‐UVB group compared with 11 of 18 participants (61.1%) in the bath PUVA groups achieved statistically significant clearance (RR 0.20, 95% CI 0.05 to 0.79; N = 34; <a href="./references#CD009481-fig-0015" title="">Analysis 2.1</a>). Because we identified moderate statistical heterogeneity between <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a> and <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a> (I² statistic = 74%), the pooled data should be interpreted with caution. </p> <p>Additionally, we conducted ITT analyses. The pooled data from <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a> and <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a> indicated that no significant difference between the two groups was identified (RR 1.79, 95% CI 0.46 to 6.91; N = 46; <a href="./references#CD009481-fig-0016" title="">Analysis 2.2</a>). Again, because of the moderate statistical heterogeneity between <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a> and <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a> (I² statistic = 52%), the pooled data should be interpreted with caution. However, the ITT analysis of <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a> found that more participants in the bath PUVA group achieved clearance than those in the NB‐UVB group (RR 0.18, 95% CI 0.18 to 0.71; N = 36; <a href="./references#CD009481-fig-0016" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD009481-sec-0118"> <h5 class="title">Secondary outcomes</h5> <p>The following four of our secondary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0119"> <h6 class="title">3) Number of treatments to clearance</h6> <p><a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a> showed that the median number of treatments to clearance for participants with CPP was 24.5 for NB‐UVB and 19 for bath PUVA, and the difference was statistically significant (P = 0.001). </p> </section> <section id="CD009481-sec-0120"> <h6 class="title">7) PASI score reduction (before and after treatment)</h6> <p><a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a> compared the PASI score reduction before and after therapy between groups in participants with CPP. The greater the reduction in score, the better the improvement in the lesions. The mean PASI score reduction was 11.71 in the NB‐UVB group and 22.51 in the bath PUVA group (MD ‐10.80, 95% CI ‐16.23 to ‐5.37; N = 34; <a href="./references#CD009481-fig-0017" title="">Analysis 2.3</a>), which was statistically in favour of bath PUVA. In the study by <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>, the median PASI score reduction was 20 in the NB‐UVB group and 17.5 in the bath PUVA group (P = 0.04). </p> </section> <section id="CD009481-sec-0121"> <h6 class="title">13) Reduction of peripheral T cells</h6> <p>In the study by <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>, in participants with CPP, the mean reduction (before‐after treatment values) of percentage of CD4+ T cells was significantly lower in NB‐UVB group than in the bath PUVA group (P = 0.03), but there was no significant difference between groups with respect to the mean change of CD8+ T cells (P = 0.27). </p> </section> <section id="CD009481-sec-0122"> <h6 class="title">15) Adverse events</h6> <p>The following adverse events were addressed in three RCTs (<a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a>) conducted in participants with CPP: erythema (in different degrees), pruritus, and folliculitis (<a href="./references#CD009481-fig-0018" title="">Analysis 2.4</a>). </p> <p><a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a> (N = 34) found no significant difference between groups with respect to the incidence of erythema (RR 1.13, 95% CI 0.18 to 7.09; N = 34; see Analysis 2.4.1), pruritus (RR 0.84, 95% CI 0.22 to 3.21; N = 34; see Analysis 2.4.2), and folliculitis (RR 0.37, 95% CI 0.02 to 8.55; N = 34; see Analysis 2.4.6). </p> <p>The study by <a href="./references#CD009481-bbs2-0002" title="DaweRS , CameronH , YuleS , ManI , WainwrightN J , IbbotsonS H , et al. A randomized controlled trial of narrowband ultraviolet B vs bath‐psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology2003;148(6):1194‐204. [MEDLINE: 12828749] ">Dawe 2003</a> (N = 28) found no significant difference between groups in terms of grade one erythema (RR 1.31, 95% CI 0.89 to 1.93; see Analysis 2.4.3), grade two erythema (RR 1.25, 95% CI 0.58 to 2.69; see Analysis 2.4.4), and grade three erythema (RR 1.00, 95% CI 0.28 to 3.61; see Analysis 2.4.5). </p> <p>However, <a href="./references#CD009481-bbs2-0011" title="SnellmanE , KlimenkoT , RantanenT . Randomized half‐side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Dermato‐Venereologica2004;84(2):132‐7. [MEDLINE: 15206693] ">Snellman 2004</a> (N = 17) found that erythema was more frequent in the NB‐UVB group than in the PUVA group (RR 1.52, 95% CI 1.07 to 2.17; see Analysis 2.4.1), which was statistically significant. </p> </section> </section> </section> <section id="CD009481-sec-0123"> <h4 class="title">3. NB‐UVB compared with topical PUVA for palmoplantar psoriasis</h4> <section id="CD009481-sec-0124"> <h5 class="title">Primary outcomes</h5> <p>Only one primary outcome was addressed for this comparison.</p> <section id="CD009481-sec-0125"> <h6 class="title">4) Clearance rate</h6> <p><a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a> conducted this within‐patient study on people with PPP. Compared with the topical PUVA treated sides, the NB‐UVB treated sides appeared harder to achieve clearance (0% versus 23.8%). However, the difference did not reach statistical significance (RR 0.09, 95% CI 0.01 to 1.55; N = 21; <a href="./references#CD009481-fig-0019" title="">Analysis 3.1</a>). <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a> did not perform ITT analysis. However, we carried out ITT analysis. The ITT analysis gave a very similar result (RR 0.09, 95% CI 0.01 to 1.56; N = 25; <a href="./references#CD009481-fig-0020" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD009481-sec-0126"> <h5 class="title">Secondary outcomes</h5> <p>The following three of our secondary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0127"> <h6 class="title">9) Relapse rate</h6> <p>In the study by <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>, the skin lesions in 12 of 21 (57.1%) NB‐UVB treated sides compared with seven of 21 (33.3%) topical PUVA treated sides relapsed at nine weeks after treatment completion, but the difference was not statistically significant (RR 1.71, 95% CI 0.84 to 3.48; N = 21; <a href="./references#CD009481-fig-0021" title="">Analysis 3.3</a>). Relapse was defined as an increase in post‐treatment Severity Index scores of PPP (see <a href="#CD009481-tbl-0006">Table 1</a>). </p> </section> <section id="CD009481-sec-0128"> <h6 class="title">12) Clinical improvement</h6> <p><a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a> compared the effect of NB‐UVB to topical PUVA in participants with PPP. The trial found that 42.9% of the sides treated with NB‐UVB achieved marked clinical improvement, while 71.4% of those sides treated with topical PUVA achieved marked clinical improvement, but the difference was not statistically significant (RR 0.60, 95% CI 0.34 to 1.05; N = 21; <a href="./references#CD009481-fig-0022" title="">Analysis 3.4</a>). In this study, marked clinical improvement was defined as those who had a reduction of 70% or more with respect to the baseline Severity Index scores at nine weeks. </p> </section> <section id="CD009481-sec-0129"> <h6 class="title">15) Adverse events</h6> <p><a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a> reported the following adverse events: phototoxicity, palmar hyperpigmentation, and mild xerosis. In this study, one participant dropped out because of a phototoxic reaction in the PUVA treated side. The incidence of palmar hyperpigmentation was significantly lower in the NB‐UVB treated side than in the PUVA treated side (0% versus 52.4%; RR 0.04, 95% CI 0.00 to 0.69; N = 21; <a href="./references#CD009481-fig-0023" title="">Analysis 3.5</a>). Mild xerosis was observed on both sides of the body and responded to emollients. </p> </section> </section> </section> <section id="CD009481-sec-0130"> <h4 class="title">4. NB‐UVB plus retinoid (re‐NB‐UVB) compared with PUVA plus retinoid (re‐PUVA) for chronic plaque or guttate psoriasis </h4> <section id="CD009481-sec-0131"> <h5 class="title">Primary outcomes</h5> <p>Two of our primary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0132"> <h6 class="title">2) Percentage of participants reaching PASI 75</h6> <p>Only one trial (<a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>) addressed this comparison in participants with chronic plaque and guttate psoriasis. <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a> found no significant difference between the two groups with respect to PASI 75 (RR 0.83, 95% CI 0.58 to 1.19; N = 52; <a href="./references#CD009481-fig-0024" title="">Analysis 4.1</a>). <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a> also reported the result of ITT analysis: 17 of 30 (56.7%) participants in the retinoid NB‐UVB group compared with 19 of 30 (63.3%) in the retinoid PUVA group reached PASI 75, but the difference between groups was not statistically significant (RR 0.89, 95% CI 0.59 to 1.35; N = 60; <a href="./references#CD009481-fig-0025" title="">Analysis 4.2</a>). </p> </section> <section id="CD009481-sec-0133"> <h6 class="title">4) Clearance rate</h6> <p><a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a> and <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a> addressed this comparison in people with chronic plaque and guttate psoriasis; pooled data found no significant difference between those who were treated with re‐NB‐UVB and those who treated re‐PUVA in terms of clearance rate (RR 0.91, 95% CI 0.78 to 1.07; N = 82; <a href="./references#CD009481-fig-0026" title="">Analysis 4.3</a>). ITT analysis of the pooled data gave a very similar result (RR 0.93, 95% CI 0.79 to 1.10; N = 90; <a href="./references#CD009481-fig-0027" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD009481-sec-0134"> <h5 class="title">Secondary outcomes</h5> <p>The following five of our secondary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0135"> <h6 class="title">7) PASI score reduction (before and after treatment)</h6> <p>In the study by <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>, in participants with chronic plaque and guttate psoriasis, the mean PASI score reduction was not significantly different between the re‐NB‐UVB group and the re‐PUVA group (11.4 versus 12.6, P = 0.83). </p> </section> <section id="CD009481-sec-0136"> <h6 class="title">9) Relapse rate</h6> <p><a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a> found no significant difference between re‐NB‐UVB and re‐PUVA with respect to relapse at six months after treatment completion (60% versus 46.7%; RR 1.29, 95% CI 0.65 to 2.54; N = 30; <a href="./references#CD009481-fig-0028" title="">Analysis 4.5</a>). Relapse was defined as a return of psoriasis to 50% or more of that at baseline. </p> </section> <section id="CD009481-sec-0137"> <h6 class="title">12) Clinical improvement</h6> <p><a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a> (N = 60) reported the percentage of participants who achieved a marked improvement (which was defined as 50% to 75% improvement in PASI score), moderate improvement (which referred to 25% to 50% improvement in PASI score), slight improvement (which referred to 5% to 25% improvement in PASI score), or no improvement (which was defined as less than 5% improvement in PASI score). Using ITT analyses, no significant differences were found between the re‐NB‐UVB group and the re‐PUVA group with respect to marked improvement (RR 1.00, 95% CI 0.28 to 3.63; <a href="./references#CD009481-fig-0029" title="">Analysis 4.6</a>, see Analysis 4.6.1), moderate improvement (RR 4.00, 95% CI 0.47 to 33.73; <a href="./references#CD009481-fig-0029" title="">Analysis 4.6</a>, see Analysis 4.6.2), slight improvement (RR 2.00, 95% CI 0.19 to 20.90; <a href="./references#CD009481-fig-0029" title="">Analysis 4.6</a>, see Analysis 4.6.3), or no improvement (RR 0.60, 95% CI 0.16 to 2.29; <a href="./references#CD009481-fig-0029" title="">Analysis 4.6</a>, see Analysis 4.6.4). </p> </section> <section id="CD009481-sec-0138"> <h6 class="title">14) Tolerability</h6> <p><a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a> (N = 60) showed there was no significant difference in the tolerability of re‐NB‐UVB or re‐PUVA when assessed by the clinicians (RR 1.05, 95% CI 0.76 to 1.44; <a href="./references#CD009481-fig-0030" title="">Analysis 4.7</a>) or by the participants themselves (RR 1.05, 95% CI 0.73 to 1.53; <a href="./references#CD009481-fig-0031" title="">Analysis 4.8</a>). </p> </section> <section id="CD009481-sec-0139"> <h6 class="title">15) Adverse events</h6> <p>Two RCTs (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>) addressed the following adverse events: erythema; pruritus; burning; diffuse hair loss; nausea; reversible hypertriglyceridaemia; dry lips, mouth, skin, and nose; joint pain; nose bleeding; taste loss; muscle pain; paronychia; xerophthalmia; nail fragility; headache; and gastrointestinal events. </p> <p>In <a href="./references#CD009481-fig-0032" title="">Analysis 4.9</a>, no significant differences were identified between re‐NB‐UVB and re‐PUVA with respect to the incidence of erythema (RR 1.32, 95% CI 0.60 to 2.94; N = 52; see Analysis 4.9.1), diffuse hair loss (RR 1.00, 95% CI 0.07 to 14.55; N = 30; see Analysis 4.9.2), reversible hypertriglyceridaemia (RR 0.33, 95% CI 0.04 to 2.85; N = 30; see Analysis 4.9.3), withdrawal due to pruritus and burning (RR 3.00, 95% CI 0.13 to 68.26; N = 30; see Analysis 4.9.4), or nausea (RR 0.33, 95% CI 0.01 to 7.58; N = 30; see Analysis 4.9.5). </p> </section> </section> </section> <section id="CD009481-sec-0140"> <h4 class="title">5. NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis</h4> <section id="CD009481-sec-0141"> <h5 class="title">Primary outcomes</h5> <p>The following two of our primary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0142"> <h6 class="title">3) Withdrawal due to side‐effects</h6> <p><a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a> found no significant difference between NB‐UVB and selective BB‐UVB with respect to withdrawals due to adverse events (RR 2.80, 95% CI 0.3 to 25.81; N = 85; <a href="./references#CD009481-fig-0033" title="">Analysis 5.1</a>); <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a> also performed ITT analysis and found a similar result (RR 3.00, 95% CI 0.32 to 27.87; N = 100; <a href="./references#CD009481-fig-0034" title="">Analysis 5.2</a>). </p> </section> <section id="CD009481-sec-0143"> <h6 class="title">4) Clearance rate</h6> <p><a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a> conducted this comparison in people with CPP. The study found there was no significant difference between the two groups with respect to clearance rate (RR 1.30, 95% CI 0.89 to 1.92; N = 85; <a href="./references#CD009481-fig-0035" title="">Analysis 5.3</a>). <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a> also performed ITT analysis and found 28 of 50 (56%) participants who received NB‐UVB compared with 20 of 50 (40%) of those who received selective BB‐UVB achieved clearance, but the difference did not reach statistical significance (RR 1.40, 95% CI 0.92 to 2.13; N = 100; <a href="./references#CD009481-fig-0036" title="">Analysis 5.4</a>). Additionally, more participants with skin type III/IV achieved clearance than those with skin type I/II, irrespective of the type of irradiation (odds of clearance = 3.22, 95% CI 1.40 to 7.43). </p> </section> </section> <section id="CD009481-sec-0144"> <h5 class="title">Secondary outcomes</h5> <p>The following four of our secondary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0145"> <h6 class="title">3) Number of treatments to clearance</h6> <p>Based on <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>, the median number of treatments to clearance was 28.4 for NB‐UVB and 30.4 for selective BB‐UVB, but the difference did not reach statistical significance (P = 0.43). In addition, the authors reported that "patients with skin type III/IV cleared faster than patients with skin type I/II," regardless of the type of irradiation. </p> </section> <section id="CD009481-sec-0146"> <h6 class="title">4) Cumulative UV dose to clearance</h6> <p>According to the <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a> trial conducted in participants with CPP, the median cumulative UV dose to clearance was 40.9 J/cm² for NB‐UVB and 39.9 J/cm² for selective BB‐UVB, but they did not report the relevant P value or 95% CI. </p> </section> <section id="CD009481-sec-0147"> <h6 class="title">6) Clearance lasting six months</h6> <p>Based on a single outcome event in the study by <a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a>, no significant difference was found in clearance lasting six months after treatment completion between those in the NB‐UVB and selective BB‐UVB groups (5.3% versus 0%; RR 2.10, 95% CI 0.09 to 47.89; N = 32; <a href="./references#CD009481-fig-0037" title="">Analysis 5.5</a>). </p> </section> <section id="CD009481-sec-0148"> <h6 class="title">15) Adverse events</h6> <p><a href="./references#CD009481-bbs2-0005" title="KirkeSM , LowderS , LloydJ , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasism [Abstract RF‐4]. The 85th BAD Annual Meeting 5‐8th July 2005, Glasgow, UK. British Journal of Dermatology2005;153(Suppl 1):10. KirkeSM , LowderS , LloydJJ , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. Journal of Investigative Dermatology2007;127(7):1641‐6. [MEDLINE: 17380117] ">Kirke 2007</a> (N = 100) reported the following adverse events: severe erythema (which caused the participants to miss treatments), PMLE, and pruritus (<a href="./references#CD009481-fig-0038" title="">Analysis 5.6</a>). There were no significant differences between NB‐UVB and selective BB‐UVB with respect to the incidence of severe erythema (RR 0.67, 95% CI 0.12 to 3.82; see Analysis 5.6.1), PMLE (RR 3.00, 95% CI 0.32 to 27.87; see Analysis 5.6.2), and pruritus (RR 0.20, 95% CI 0.01 to 4.06; see Analysis 5.6.3). </p> </section> </section> </section> <section id="CD009481-sec-0149"> <h4 class="title">6. NB‐UVB compared with conventional BB‐UVB in people with different types of psoriasis</h4> <section id="CD009481-sec-0150"> <h5 class="title">Primary outcomes</h5> <p>No included studies addressed our primary outcomes for this comparison.</p> </section> <section id="CD009481-sec-0151"> <h5 class="title">Secondary outcomes</h5> <p>Only the following two of our secondary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0152"> <h6 class="title">4) Cumulative UV dose to clearance</h6> <p>Two RCTs (<a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) addressed this outcome; both trials conducted half‐body irradiations by left‐right comparison. Because there were insufficient data available in <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>, meta‐analysis could not be performed. In <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a> (N = 10), the mean cumulative UV dose during the study that was statistically significant was 14.68 J/cm² with NB‐UVB and 1.427 J/cm² with conventional BB‐UVB (MD 13.25, 95% CI 7.11 to 19.39; <a href="./references#CD009481-fig-0039" title="">Analysis 6.1</a>). By contrast, in <a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>, the mean cumulative UV dose was 0.83 J/cm² with NB‐UVB and 4.8 J/cm² with conventional BB‐UVB (P value or 95% CI was not reported). </p> </section> <section id="CD009481-sec-0153"> <h6 class="title">7) PASI score reduction (before and after treatment)</h6> <p><a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a> compared NB‐UVB with conventional BB‐UVB in 10 participants with different types of psoriasis. The total decrease of the PASI was significantly greater with NB‐UVB than with conventional BB‐UVB (P &lt; 0.05). </p> </section> </section> </section> <section id="CD009481-sec-0154"> <h4 class="title">7. NB‐UVB plus dithranol compared with conventional BB‐UVB plus dithranol in people with different types of psoriasis </h4> <section id="CD009481-sec-0155"> <h5 class="title">Primary outcomes</h5> <p>No included studies addressed our primary outcomes for this comparison.</p> </section> <section id="CD009481-sec-0156"> <h5 class="title">Secondary outcomes</h5> <p>Only the following two of our secondary outcomes were addressed for this comparison.</p> <section id="CD009481-sec-0157"> <h6 class="title">4) Cumulative UV dose to clearance</h6> <p><a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a> also compared NB‐UVB plus dithranol with conventional BB‐UVB plus dithranol in 13 participants with different types of psoriasis. The mean cumulative UV dose during the study that was statistically significant was 10.93 J/cm² for NB‐UVB and 1.3 J/cm² for conventional BB‐UVB (MD 9.63, 95% CI 7.09 to 12.17; <a href="./references#CD009481-fig-0040" title="">Analysis 7.1</a>). </p> </section> <section id="CD009481-sec-0158"> <h6 class="title">7) PASI score reduction (before and after treatment)</h6> <p><a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a> compared NB‐UVB plus dithranol with conventional BB‐UVB plus dithranol in 13 participants with different types of psoriasis. The total decrease of the PASI was statistically significantly greater with NB‐UVB than with conventional BB‐UVB (P &lt; 0.05). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009481-sec-0159" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009481-sec-0159"></div> <section id="CD009481-sec-0160"> <h3 class="title" id="CD009481-sec-0160">Summary of main results</h3> <p>We included 13 RCTs, with 662 participants, in this review, and the main results are listed as follows. </p> <p><b>NB‐UVB compared with oral PUVA in people with chronic plaque psoriasis</b>: The percentage of participants reaching PASI 75 showed no statistically significant difference between the NB‐UVB group and the oral PUVA group, and the ITT analysis gave a similar result. Pooled data from three RCTs indicated that withdrawals due to adverse events were not significantly different between the NB‐UVB and the oral PUVA groups, and the ITT analysis gave a similar result. The clearance rate between groups was not consistent within the three included studies because in one, there was no difference between the groups, and in the other two, the clearance rate was statistically significantly in favour of oral PUVA. In one of these two studies, clearance was measured at six months, which was achieved by statistically significantly more participants in the oral PUVA group. </p> <p>The median number of treatments to clearance was significantly lower in the oral PUVA group compared with NB‐UVB, but time to clearance was similar between the two groups. The cumulative UV dose to clearance, relapse rate at six months after treatment, and duration of remission were not significantly different between the groups. Moreover, the participants' QOL in the oral PUVA group was improved more than in the NB‐UVB group. Nausea was significantly higher in the oral PUVA group. </p> <p><b>Narrow‐band UVB compared with bath PUVA in people with chronic plaque psoriasis</b>: The evidence addressing this comparison was not consistent. Two RCTs, which performed left‐right body comparison, found no significant difference between the NB‐UVB and bath PUVA groups, while another RCT, which performed the comparison between participants, favoured bath PUVA. Intention‐to‐treat (ITT) analyses did not significantly change the results. </p> <p><b>Narrow‐band UVB compared with topical PUVA in people with palmoplantar psoriasis</b>: There were no significant differences between NB‐UVB treated sides and topical PUVA treated sides in terms of clearance rate, marked improvement rate, and relapse rate. The incidence of palmar hyperpigmentation was statistically significantly higher in the PUVA treated sides. </p> <p><b>Retinoid NB‐UVB compared with retinoid PUVA in people with chronic plaque or guttate psoriasis</b>: No significant difference was found between re‐NB‐UVB and re‐PUVA with respect to effectiveness, tolerability, and adverse events, irrespective of using the retinoids, etretinate or acitretin, as adjuvant therapy. </p> <p><b>Narrow‐band UVB compared with selective BB‐UVB in people with chronic plaque psoriasis</b>: No significant differences were found between those treated with NB‐UVB and those treated with selective BB‐UVB in terms of withdrawal due to side‐effects, clearance rate, number of treatments to clearance, cumulative UV dose to clearance, and adverse events. </p> <p><b>Narrow‐band UVB compared with conventional BB‐UVB in people with different types of psoriasis</b>: Based on one small RCT, NB‐UVB seemed to be more effective than conventional BB‐UVB. However, cumulative UV dose to clearance in both groups was not consistent between the two included RCTs. </p> <p><b>Narrow‐band UVB plus dithranol compared with conventional BB‐UVB plus dithranol in people with different types of psoriasis</b>: Based on a small RCT, NB‐UVB plus dithranol seemed to be more effective than conventional BB‐UVB plus dithranol. However, cumulative UV dose to clearance was higher in the NB‐UVB group than the BB‐UVB group. </p> </section> <section id="CD009481-sec-0161"> <h3 class="title" id="CD009481-sec-0161">Overall completeness and applicability of evidence</h3> <p>Most included RCTs in this review were conducted in adults with psoriasis, but one RCT (<a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>) enrolled participants aged more than 13 years, while another RCT (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>) did not report the age of the participants. The results of this review should therefore be applied to adults as the literature regarding the use of phototherapy in paediatric patients with psoriasis is limited (<a href="./references#CD009481-bbs2-0057" title="MenterA , KormanNJ , ElmetsCA , FeldmanSR , GelfandJM , GordonKB , et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology2010;62(1):114‐35. [MEDLINE: 19811850] ">Menter 2010</a>). In addition, these RCTs either did not include or separately reported pregnant women, and in consequence, our review did not contribute to this specific population. However, a recent guideline reported that NB‐UVB has been used successfully in pregnant women with psoriasis and "should be considered first‐line therapy in pregnant women with plaque and guttate psoriasis who need a systemic approach to treatment" (<a href="./references#CD009481-bbs2-0057" title="MenterA , KormanNJ , ElmetsCA , FeldmanSR , GelfandJM , GordonKB , et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology2010;62(1):114‐35. [MEDLINE: 19811850] ">Menter 2010</a>). Moreover, because most of the included participants suffered from chronic plaque psoriasis (CPP), the evidence for guttate psoriasis and palmoplantar psoriasis was limited, and only one trial (NB‐UVB compared with selective BB‐UVB) included participants with erythrodermic psoriasis. </p> <p>In recent years, NB‐UVB has replaced conventional BB‐UVB as the first‐line treatment for psoriasis and has been recommended by US and UK guidelines (<a href="./references#CD009481-bbs2-0057" title="MenterA , KormanNJ , ElmetsCA , FeldmanSR , GelfandJM , GordonKB , et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology2010;62(1):114‐35. [MEDLINE: 19811850] ">Menter 2010</a>; <a href="./references#CD009481-bbs2-0068" title="SmithCH , AnsteyAV , BarkerJN , BurdenAD , ChalmersRJ , ChandlerDA , et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology2009;161(5):987‐1019. [MEDLINE: 19857207] ">Smith 2009</a>), respectively, or used in clinical practice. In the most recently published guideline (<a href="./references#CD009481-bbs2-0064" title="PaulC , GalliniA , ArchierE , CastelaE , DevauxS , AractingiS , et al. Evidence‐based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 3):1‐10. [MEDLINE: 22512675] ">Paul 2012</a>), neither conventional or selective BB‐UVB has been mentioned. In this review, we identified only two RCTs (<a href="./references#CD009481-bbs2-0006" title="LarkoO . Treatment of psoriasis with a new UVB‐lamp. Acta Dermato‐Venereologica1989;69(4):357‐9. [EMBASE: 1989165254] ">Larko 1989</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) that compared NB‐UVB with conventional BB‐UVB; both of the studies were of high risk of bias and small sample sizes. They gave contrasting results with respect to cumulative UV dose to clearance; however, <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a> showed that NB‐UVB achieved a greater PASI score reduction than conventional BB‐UVB. It is noteworthy that many non‐RCTs (<a href="./references#CD009481-bbs2-0015" title="CovenTR , BurackLH , GilleaudeauR , KeoghM , OzawaM , KruegerJG . Narrowband UV‐B produces superior clinical and histopathological resolution of moderate‐to‐severe psoriasis in patients compared with broadband UV‐B. Archives of Dermatology1997;133(12):1514‐22. [MEDLINE: 9420535] ">Coven 1997</a>; <a href="./references#CD009481-bbs2-0051" title="KarvonenJ , KokkonenE L , RuotsalainenE . 311 nm UVB lamps in the treatment of psoriasis with the Ingram regimen. Acta Dermato‐Venereologica1989;69(1):82‐5. [MEDLINE: 2563617] ">Karvonen 1989</a>; <a href="./references#CD009481-bbs2-0065" title="PicotE , MeunierL , Picot‐DebezeMC , PeyronJL , MeynadierJ . Treatment of psoriasis with a 311‐nm UVB lamp. British Journal of Dermatology1992;127(5):509‐12. [MEDLINE: 1467291] ">Picot 1992</a>; <a href="./references#CD009481-bbs2-0072" title="WaltersIB , BurackLH , CovenTR , GilleaudeauP , KruegerJG . Suberythemogenic narrow‐band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. Journall of American Academic Dermatology1999;40(6 Pt 1):893‐900. [MEDLINE: 10365919] ">Walters 1999</a>) indicate that NB‐UVB is preferable to conventional BB‐UVB. The dosage and duration of phototherapy in different trials varied from each other, and no RCT so far has directly compared different dosing strategies and frequency of application. </p> <p>Most included RCTs applied clearance, minimal residual activity (MRA), PASI, and clinical improvement as the main outcomes, which were subjective and measured by clinicians. Only one RCT (<a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) assessed quality of life, an important outcome for people with psoriasis. </p> <p>Additionally, the risk of carcinogenesis as a result of phototherapy attracted the greatest concern by the participants and clinicians. Because of the limited duration of follow‐up, none of the included RCTs addressed this important issue. A clear relationship between cumulative PUVA exposure and an increased risk of skin cancer had been established (<a href="./references#CD009481-bbs2-0060" title="NaldiL . Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clinics in Dermatology2010;28(1):88‐92. [MEDLINE: 20082957] ">Naldi 2010</a>; <a href="./references#CD009481-bbs2-0064" title="PaulC , GalliniA , ArchierE , CastelaE , DevauxS , AractingiS , et al. Evidence‐based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 3):1‐10. [MEDLINE: 22512675] ">Paul 2012</a>; <a href="./references#CD009481-bbs2-0068" title="SmithCH , AnsteyAV , BarkerJN , BurdenAD , ChalmersRJ , ChandlerDA , et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. British Journal of Dermatology2009;161(5):987‐1019. [MEDLINE: 19857207] ">Smith 2009</a>), but there is controversy regarding the risk of skin cancer with NB‐UVB or BB‐UVB (<a href="./references#CD009481-bbs2-0073" title="WeischerM , BlumA , EberhardF , RockenM , BerneburgM . No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Dermato‐Venereologica2004;84(5):370‐4. [MEDLINE: 15370703] ">Weischer 2004</a>). <a href="./references#CD009481-bbs2-0074" title="YoungAR . Carcinogenicity of UVB phototherapy assessed. Lancet1995;345(8962):1431‐2. [DOI: 10.1016/S0140‐6736(95)92617‐8] ">Young 1995</a> summarised data from murine studies and reported that NB‐UVB might be two to three times more carcinogenic per minimal erythema dose (MED) than conventional BB‐UVB. However, the following systematic reviews of trials conducted in people with psoriasis (<a href="./references#CD009481-bbs2-0045" title="HearnRM , KerrAC , RahimKF , FergusonJ , DaweRS . Incidence of skin cancers in 3867 patients treated with narrow‐band ultraviolet B phototherapy. British Journal of Dermatology2008;159(4):931‐5. [MEDLINE: 18834483] ">Hearn 2008</a>; <a href="./references#CD009481-bbs2-0055" title="LeeE , KooJ , BergerT . UVB phototherapy and skin cancer risk: a review of the literature. International Journal of Dermatology2005;44(5):355‐60. [MEDLINE: 15869531] ">Lee 2005</a>; <a href="./references#CD009481-bbs2-0063" title="Pasker‐de JongPC , WielinkG , van derValkPG , van derWiltGJ . Treatment with UV‐B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Archives of Dermatology1999;135(7):834‐40. [MEDLINE: 10411159] ">Pasker‐de 1999</a>) found that UVB did not increase the risk of skin cancer. Most recently, <a href="./references#CD009481-bbs2-0023" title="ArchierE , DevauxS , CastelaE , GalliniA , AubinF , LeMaitreM , et al. Carcinogenic risks of psoralen UV‐A therapy and narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 3):22‐31. [MEDLINE: 22512677] ">Archier 2012</a> found no robust evidence of carcinogenic risk of NB‐UVB because of limited prospective studies. </p> </section> <section id="CD009481-sec-0162"> <h3 class="title" id="CD009481-sec-0162">Quality of the evidence</h3> <p>The included trials were of varying methodological quality. In general, these trials did not fully follow good practice conduct and reporting guidelines, such as CONSORT (Consolidated Standards of Reporting Trials) (<a href="./references#CD009481-bbs2-0067" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Medicine2010;7(3):e1000251. [MEDLINE: 20352064] ">Schulz 2010</a>). First, although all of the studies stated the participants (or half‐bodies) were randomly allocated, four of them (<a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) did not explicitly report the methods of randomisation. Second, allocation concealment was not clearly mentioned in six trials (<a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0008" title="ÖzdemirM , EnginB , BaysalI , MevlitogluI . A randomized comparison of acitretin‐narrow‐band TL‐01 phototherapy and acitretin‐psoralen plus ultraviolet A for psoriasis. Acta Dermato‐Venereologica2008;88(6):589‐93. [MEDLINE: 19002344] ">Özdemir 2008</a>; <a href="./references#CD009481-bbs2-0009" title="SalemSA , BarakatMA , MorcosCM . Bath psoralen+ultraviolet A photochemotherapy vs. narrow band‐ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T‐helper and T‐suppressor/cytotoxic cells. Photodermatology, Photoimmunology &amp; Photomedicine2010;26(5):235‐42. [MEDLINE: 20831697] ">Salem 2010</a>; <a href="./references#CD009481-bbs2-0010" title="SezerE , ErbilAH , KurumluZ , TastanHB , EtikanI . Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. Journal of Dermatology2007;34(7):435‐40. [MEDLINE: 17584319] ">Sezer 2007</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>), while another trial (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>) explicitly stated that allocation concealment was not performed. Insufficient randomisation or allocation concealment might cause potential selection bias. Third, using clearance, minimal residual activity (MRA), or PASI score as the end points was subjective and relatively imprecise. Thus, it is important to blind the evaluating observers to treatment allocation and treatment supervision. One included trial (<a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>) did not apply blinding; the other three trials (<a href="./references#CD009481-bbs2-0001" title="ChauhanPS , KaurI , DograS , DeD , KanwarAJ . Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective. Clinical &amp; Experimental Dermatology2011;36(2):169‐73. [MEDLINE: 20545955] ">Chauhan 2011</a>; <a href="./references#CD009481-bbs2-0004" title="GreenC , LakshmipathiT , JohnsonBE , FergusonJ . A comparison of the efficacy and relapse rates of narrowband UVB (TL‐01) monotherapy vs. etretinate (re‐TL‐01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. British Journal of Dermatology1992;127(1):5‐9. [MEDLINE: 1637696] ">Green 1992</a>; <a href="./references#CD009481-bbs2-0012" title="StorbeckK , HolzleE , SchurerN , LehmannP , PlewigG . Narrow‐band UVB (311 nm) versus conventional broad‐band UVB with and without dithranol in phototherapy for psoriasis. Journal of the American Academy of Dermatology1993;28(2 Pt 1):227‐31. [MEDLINE: 8432920] ">Storbeck 1993</a>) did not report whether blinding was used or not. Lack of blinding might cause an overestimation of the effects. It should be noted that different types of phototherapies were performed in different irradiation devices. Besides, PUVA needs use of a photosensitiser (in oral, bath, or topical form), while NB‐UVB does not. Hence, it was hard to blind therapists and participants. Fourth, seven of 12 trials had more than 10% dropouts, but only two of them performed ITT analysis, which may be useful to maintain the unbiased group comparison supplied by randomisation. Lack of ITT analysis might lead to potential biases. Last but not least, the sample sizes of these included trials were generally small, which might compromise the value of the results. In a disease with poorly defined treatment outcome measures, small sample size might lead to an underpowered study. </p> </section> <section id="CD009481-sec-0163"> <h3 class="title" id="CD009481-sec-0163">Potential biases in the review process</h3> <p>We experienced some limitations during the review process. One published study (<a href="./references#CD009481-bbs2-0021" title="NazariS , OzarmaganG , ErzenginD , AkarU . A randomized comparison of narrow‐band UVB phototherapy and PUVA photochemotherapy in the management of plaque‐type psoriasis [Psoriasiste PUVA ve dar bant UVB tedavilerinin klinik etkinliklerinin karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi2005;39(2):103‐8. [EMBASE: 2006204570] ">Nazari 2005</a>) appeared to meet the inclusion criteria, but we have not yet been able to include or exclude this study. Requests for unpublished data from the authors of some included trials failed, and as a consequence, meta‐analysis could not be performed for some outcomes and comparisons. Therefore, the results of this review have to be interpreted with caution. </p> </section> <section id="CD009481-sec-0164"> <h3 class="title" id="CD009481-sec-0164">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review (<a href="./references#CD009481-bbs2-0024" title="ArchierE , DevauxS , CastelaE , GalliniA , AubinF , LeMaitreM , et al. Efficacy of psoralen UV‐A therapy vs. narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 3):11‐21. [MEDLINE: 22512676] ">Archier 2012a</a>), which was published most recently, included three RCTs (<a href="./references#CD009481-bbs2-0003" title="GordonPM , DiffeyBL , FarrPM . A comparison of narrow‐band TL01 phototherapy and psoralen‐UVA photochemotherapy for psoriasis [Summary]. British Journal of Dermatology1997;137(Suppl 50):15. [DOI: 10.1111/j.1365‐2133.1997.tb01879.x] GordonPM , DiffeyBL , MatthewsJN , FarrPM . A randomized comparison of narrow‐band TL‐01 phototherapy and PUVA photochemotherapy for psoriasis. Journal of the American Academy of Dermatology1999;41(5 Pt 1):728‐32. [MEDLINE: 10534635] ">Gordon 1999</a>; <a href="./references#CD009481-bbs2-0007" title="MarkhamT , RogersS , CollinsP . A comparison of oral 8‐methoxypsoralen PUVA and narrowband UVB (TL‐OI) phototherapy in the management of chronic plaque psoriasis [Summary]. British Journal of Dermatology2001;145(Suppl 59):25. [DOI: 10.1046/j.1365‐2133.2001.012ff.x] MarkhamT , RogersS , CollinsP . Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Archives of Dermatology2003;139(3):325‐8. [MEDLINE: 12622624] ">Markham 2003</a>; <a href="./references#CD009481-bbs2-0013" title="YonesSS , GaribadinosT , SeedP , CsaszarM , HawkJ . A prospective randomized double blind trial of the efficacy of narrowband UVB (TL01) phototherapy and psoralen photochemotherapy (PUVA) in the treatment of chronic plaque psoriasis (CPP) [Abstract FC11.10]. 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12‐15th October 2005. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):47. [DOI: 10.1111/j.1468‐3083.2005.01310.x] YonesSS , PalmerRA , GaribaldinosTT , HawkJL . Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Archives of Dermatology2006;142(7):836‐42. [MEDLINE: 16847198] ">Yones 2006</a>) that compared NB‐UVB with PUVA in people with chronic plaque psoriasis. We included all three of these RCTs in our review. <a href="./references#CD009481-bbs2-0024" title="ArchierE , DevauxS , CastelaE , GalliniA , AubinF , LeMaitreM , et al. Efficacy of psoralen UV‐A therapy vs. narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 3):11‐21. [MEDLINE: 22512676] ">Archier 2012a</a> did not include RCTs that compared NB‐UVB with bath PUVA, and the outcomes were slightly different to those in our review: They combined "clearance" with "clearance or MRA" as a single outcome, whereas we reported them separately. In addition, we reported more secondary outcomes; however, the authors drew a similar conclusion, which was that both PUVA and NB‐UVB were effective for treating CPP, but oral PUVA was more effective than NB‐UVB to "clear psoriasis, with fewer sessions, provided longer lasting clearance, and should therefore still be used in appropriate selected patients". </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009481-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD009481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: Review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD009481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: Review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: Review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD009481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: Review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 1 PASI 75." data-id="CD009481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 1 PASI 75.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 2 PASI 75 (ITT analysis)." data-id="CD009481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 2 PASI 75 (ITT analysis).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 3 Withdrawals due to side‐effects." data-id="CD009481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 3 Withdrawals due to side‐effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 4 Withdrawals due to side‐effects (ITT analysis)." data-id="CD009481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 4 Withdrawals due to side‐effects (ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 5 Clearance rate." data-id="CD009481-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 5 Clearance rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 6 Clearance rate (ITT analysis)." data-id="CD009481-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 6 Clearance rate (ITT analysis).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 7 Clearance lasting 6 months." data-id="CD009481-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 7 Clearance lasting 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 8 Time to PASI 75." data-id="CD009481-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 8 Time to PASI 75.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 9 Relapse rate at 6 months after treatment completion." data-id="CD009481-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 9 Relapse rate at 6 months after treatment completion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 10 Withdrawals due to poor response." data-id="CD009481-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 10 Withdrawals due to poor response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 11 Adverse events." data-id="CD009481-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 NB‐UVB versus oral PUVA in CPP, Outcome 11 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 1 Clearance rate." data-id="CD009481-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 1 Clearance rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 2 Clearance rate (ITT analysis)." data-id="CD009481-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 2 Clearance rate (ITT analysis).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 3 PASI score reduction." data-id="CD009481-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 3 PASI score reduction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 4 Adverse events." data-id="CD009481-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 NB‐UVB versus bath PUVA in CPP, Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 1 Clearance rate." data-id="CD009481-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 1 Clearance rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 2 Clearance rate (ITT analysis)." data-id="CD009481-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 2 Clearance rate (ITT analysis).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 3 Relapse at 9 weeks after treatment completion." data-id="CD009481-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 3 Relapse at 9 weeks after treatment completion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 4 Marked improvement." data-id="CD009481-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 4 Marked improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 5 Adverse events." data-id="CD009481-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 NB‐UVB versus topical PUVA in PPP, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 1 PASI." data-id="CD009481-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 1 PASI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 2 PASI 75 (ITT analysis)." data-id="CD009481-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 2 PASI 75 (ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 3 Clearance rate." data-id="CD009481-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 3 Clearance rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 4 Clearance rate (ITT analysis)." data-id="CD009481-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 4 Clearance rate (ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 5 Relapse at 6 months after treatment completion." data-id="CD009481-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 5 Relapse at 6 months after treatment completion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 6 Clinical improvement." data-id="CD009481-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 6 Clinical improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 7 Tolerability assessed as good or very good by observers (ITT analysis)." data-id="CD009481-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 7 Tolerability assessed as good or very good by observers (ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 8 Tolerability assessed as good or very good by participants (ITT analysis)." data-id="CD009481-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 8 Tolerability assessed as good or very good by participants (ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 9 Adverse events." data-id="CD009481-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis, Outcome 9 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 1 Withdrawal due to side‐effects." data-id="CD009481-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 1 Withdrawal due to side‐effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 2 Withdrawals due to side‐effects (ITT analysis)." data-id="CD009481-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 2 Withdrawals due to side‐effects (ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 3 Clearance rate." data-id="CD009481-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 3 Clearance rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 4 Clearance rate (ITT analysis)." data-id="CD009481-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 4 Clearance rate (ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 5 Clearance lasting 6 months." data-id="CD009481-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 5 Clearance lasting 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 6 Adverse events." data-id="CD009481-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 NB‐UVB versus selective BB‐UVB in CPP, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 NB‐UVB versus conventional BB‐UVB in different types of psoriasis, Outcome 1 Cumulative UV dose during the study." data-id="CD009481-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 NB‐UVB versus conventional BB‐UVB in different types of psoriasis, Outcome 1 Cumulative UV dose during the study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009481-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/urn:x-wiley:14651858:media:CD009481:CD009481-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_t/tCD009481-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 NB‐UVB plus dithranol versus conventional BB‐UVB plus dithranol in different types of psoriasis, Outcome 1 Cumulative UV dose during the study." data-id="CD009481-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 NB‐UVB plus dithranol versus conventional BB‐UVB plus dithranol in different types of psoriasis, Outcome 1 Cumulative UV dose during the study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/media/CDSR/CD009481/image_n/nCD009481-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009481-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NB‐UVB compared with oral PUVA for chronic plaque psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>NB‐UVB compared with oral PUVA for chronic plaque psoriasis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Oral PUVA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral PUVA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>720 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>655 per 1000</b> <br/> (454 to 950) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> <br/> (0.63 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> <p>(7 to 82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b> <br/> (0.20 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (3 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The results of 3 small RCTs are contradictory. Because of the significant statistical heterogeneity, the data were not pooled </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ The study was of small sample size.<br/> ² The study was at high risk of bias.<br/> ³ All of the 3 studies were of small sample size and at high risk of bias, and the result was based on less than 300 participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">NB‐UVB compared with oral PUVA for chronic plaque psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009481-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NB‐UVB compared with bath PUVA for chronic plaque psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB compared with bath PUVA for chronic plaque psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Bath PUVA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bath PUVA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (160 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.79</b> <br/> (0.46 to 6.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. On the basis of studies performing left‐right body comparison. 2. This is the result of ITT analysis </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>611 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b> <br/> (31 to 434) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.18</b> <br/> (0.05 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>², ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. On the basis of the study performing comparison between participants. 2. This is the result of ITT analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in the footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ Both of the studies were of small sample size and at high risk of bias, and the result was based on less than 300 participants.<br/> ² The study was at high risk of bias.<br/> ³ The study was of small sample size, and the result was based on less than 300 participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NB‐UVB compared with bath PUVA for chronic plaque psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009481-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NB‐UVB compared with topical PUVA for palmoplantar psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB compared with topical PUVA for palmoplantar psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with palmoplantar psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Topical PUVA </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topical PUVA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> <br/> (2 to 312) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b> <br/> (0.01 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ This study was at unclear risk of bias.<br/> ² The study was of small sample size, and the result was based on less than 300 participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NB‐UVB compared with topical PUVA for palmoplantar psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009481-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">NB‐UVB plus retinoid compared with PUVA plus retinoid for chronic plaque or guttate psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB plus retinoid compared with PUVA plus retinoid for chronic plaque or guttate psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque or guttate psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB plus retinoid<br/> <b>Comparison:</b> PUVA plus retinoid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PUVA plus retinoid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB plus retinoid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.59 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>633 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> <br/> (374 to 855) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>756 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>688 per 1000</b> <br/> (544 to 831) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.79 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>², ³ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ This study was at high risk of bias.<br/> ² The studies were of small sample size, and the result was based on less than 300 people.<br/> ³ Both of the studies were at high risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">NB‐UVB plus retinoid compared with PUVA plus retinoid for chronic plaque or guttate psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009481-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with chronic plaque psoriasis<br/> <b>Settings:</b> ‐<br/> <b>Intervention:</b> NB‐UVB<br/> <b>Comparison:</b> Selective BB‐UVB </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Selective BB‐UVB</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> NB‐UVB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant‐rated global improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Percentage of participants reaching PASI 75</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No included RCT addressed this outcome</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Withdrawal due to side‐effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.00</b> <br/> (0.32 to 27.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> <br/> (6 to 557) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clearance rate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b> <br/> (368 to 852) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> <br/> (0.92 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹, ² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This is the result of ITT analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Comment: The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ The study was at unclear risk of bias.<br/> ² The study was of small sample size, and the result was based on less than 300 people. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">NB‐UVB compared with selective BB‐UVB for chronic plaque psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009481-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of some important terms and abbreviations used</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Medical term and abbreviations</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Apoptosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of programmed cell death that occurs during growth and development of multicellular organisms. It is generally considered a part of normal cell aging, but it can also be a response to cellular injury </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>BB‐UVB</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Broad‐band ultraviolet B</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Collagenase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme that breaks the peptide bonds in collagen</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CPP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic plaque psoriasis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cytokines</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small protein molecules that are secreted by cells of the nervous system or the immune system. They are used in intercellular communication </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Defective maturation of epidermal keratinocytes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete formation of keratin (the horny material in nails) due to rapid growth of cells in the epidermal layer of the skin </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dilatation of dermal capillaries</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dilation of small blood vessels in the skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythrodermic psoriasis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A subtype of psoriasis that affects nearly all body sites</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythrogenic response</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness of the skin caused by light exposure</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extensor aspects</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An anatomical term ‐ when a joint bends, the parts of the skin on the opposite side of the joint are called the extensor aspects </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperkeratosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thickening of the stratum corneum (outermost layer of the skin) usually associated with an abnormality of the keratin and an increase of the granular layer of the skin </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperplasia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An increase in the number of cells</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperproliferation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An abnormally high rate of proliferation of cells by rapid division</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypertriglyceridaemia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High levels of triglyceride fatty acids</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intention‐to‐treat: An ITT analysis is often recommended as the least biased way to estimate intervention effects in RCTs. The principals of ITT analysis are as follows: 1. keep participants in the intervention group to which they were randomised, regardless of the intervention they actually received; 2. measure outcome data on all participants; and 3. include all randomised participants in the analysis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MRA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimal residual activity</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MOP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methoxypsoralen</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NB‐UVB</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narrow‐band ultraviolet B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Paronychia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling of the skin over the nail</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PASI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psoriasis Area and Severity Index. The higher the score, the more severe the lesions are </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PASI 75</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equal to or more than 75% reduction in PASI score</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmoplantar psoriasis</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Psoralen</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A compound that can be used as a kind of photosensitiser to improve the influence of natural or artificial light </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PUVA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psoralen plus ultraviolet A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Photosensitiser</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical treatments that are used to sensitise the skin and enhance the effect of light treatments </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pustular</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lesions containing purulent materials</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QOL</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Re‐NB‐UVB</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NB‐UVB combined with retinoid</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Re‐PUVA</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PUVA combined with retinoid</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severity index of PPP</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A tool developed by <a href="./references#CD009481-bbs2-0047" title="HoferA , Fink‐PuchesR , KerlH , QuehenbergerF , WolfP . Paired comparison of bath water versus oral delivery of 8‐methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis.. Photodermatol Photoimmunol Photomed2006;22:1‐5. ">Hofer 2006</a> to evaluate the severity of palmoplantar psoriasis. The separate scores of erythema, scaling, pustulation, and infiltration for palms and soles were added to calculate the severity index (0 = absent; 1 = slight; 2 = moderate; 3 = marked; and 4 = very marked) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Xerophthalmia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dryness of the eye, especially the cornea and conjunctiva</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Xerosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Extreme dryness of the skin</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of some important terms and abbreviations used</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/full#CD009481-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009481-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NB‐UVB versus oral PUVA in CPP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 PASI 75 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PASI 75 (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to side‐effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.19, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to side‐effects (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.20, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clearance rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clearance rate (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clearance lasting 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Time to PASI 75 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Relapse rate at 6 months after treatment completion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.74, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawals due to poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.47, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.31, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 PMLE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.16, 6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 grade 1 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 grade 2 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.13, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 any adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.40, 2.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NB‐UVB versus oral PUVA in CPP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009481-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NB‐UVB versus bath PUVA in CPP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies performing left‐right body comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.29, 14.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Study performing comparison between participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clearance rate (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies performing left‐right body comparison</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.46, 6.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Studies performing comparisons between participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PASI score reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 grade 1 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 grade 2 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 grade 3 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 folliculitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 any adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NB‐UVB versus bath PUVA in CPP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009481-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NB‐UVB versus topical PUVA in PPP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clearance rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clearance rate (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Relapse at 9 weeks after treatment completion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Marked improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 palmar hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NB‐UVB versus topical PUVA in PPP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009481-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 PASI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PASI 75 (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clearance rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clearance rate (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Relapse at 6 months after treatment completion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clinical improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Marked improvement (50% to 75% improvement in PASI, ITT analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Moderate improvement (25% to 50% improvement in PASI, ITT analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Slight improvement (5% to 25% improvement in PASI, ITT analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 No improvement (&lt; 5% improvement in PASI, ITT analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Tolerability assessed as good or very good by observers (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Tolerability assessed as good or very good by participants (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 diffuse hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 reversible hypertriglyceridaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 withdrawal due to pruritus and burning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">NB‐UVB plus retinoid versus PUVA plus retinoid in chronic plaque or guttate psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009481-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NB‐UVB versus selective BB‐UVB in CPP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to side‐effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals due to side‐effects (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clearance rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clearance rate (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clearance lasting 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 severe erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PMLE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NB‐UVB versus selective BB‐UVB in CPP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009481-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">NB‐UVB versus conventional BB‐UVB in different types of psoriasis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cumulative UV dose during the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">NB‐UVB versus conventional BB‐UVB in different types of psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009481-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">NB‐UVB plus dithranol versus conventional BB‐UVB plus dithranol in different types of psoriasis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cumulative UV dose during the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">NB‐UVB plus dithranol versus conventional BB‐UVB plus dithranol in different types of psoriasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009481.pub2/references#CD009481-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009481.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009481-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009481-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009481-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD009481-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009481-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009481\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009481\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009481\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009481\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009481.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009481.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009481.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726276005"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009481.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726276009"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009481.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8fb07a9ff431',t:'MTc0MDcyNjI3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 